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The Function of Peroxisome Proliferator-Activated Receptor-Gamma in the Urothelium 
Chang Liu 
 
The urothelium is a stratified epithelium that serves as a barrier between the urinary tract 
and blood. It consists of terminally differentiated umbrella cells, which are specialized for 
synthesizing and assembling uroplakins into a tough apical plaque and responsible for the barrier 
function; intermediate cells which are few in number but serve as umbrella cell progenitors; and 
unipotent basal cells, which populate the majority of the urothelium. The urothelium is one of the 
most quiescent epithelia in the body but can rapidly regenerate in response to damage.  
The urothelium is also a source of cells that give rise to bladder cancer. Patients with 
chronic inflammation caused by indwelling catheters or repeated urinary tract infections have a 
higher risk of developing bladder cancer. Bladder cancers with squamous histological features 
are considered to be more aggressive with poor prognosis and the majority are categorized as 
basal subtype. The expression of Peroxisome Proliferator-Activated Receptor-gamma (PPARG) 
is strongly down regulated in the basal subtype of bladder cancer, suggesting that its removal 
might be essential in tumorigenesis.  
PPARG is a nuclear hormone receptor that was originally described as a master regulator 
of adipogenesis but could also promote cellular differentiation in a number of epithelium. 
PPARG also serves as an important regulator in anti-inflammatory activity after a variety of 
injuries, acting in part by antagonizing the NF-kB pathway. In urothelial cells, it has been shown 
that PPARG promotes urothelial differentiation in vitro, but its function in vivo remains 
unexplored.  
 To determine the role of PPARG in vivo, we used Cre-Lox recombination to 
conditionally delete the Pparg gene in the mouse urothelium using the ShhCre driver, which 
drives recombination in basal and intermediate cells, and their respective daughters. 
Interestingly, ShhCre;Ppargfl/fl mutants lack umbrella and intermediate cells which normally 
populate the luminal and sub-luminal layers, and are instead populated with an abnormal cell 
population negative for classical urothelial markers. The basal compartment, which in wild type 
mice is largely populated by P63+ KRT5+ basal cells with a small sub-population expressing 
KRT14; has an increased number of KRT14-expressing cells in the mutants and exhibits 
squamous features that are not present in the normal urothelium.  
In wild type animals, urinary tract infection (UTI) with uropathogenic E.coli results in a 
transient innate immune response, followed by proliferation and repair, which is largely 
complete within 2 weeks. When ShhCre;Ppargfl/fl mutants were challenged with urinary tract 
infection, the innate immune response was not resolved even after several weeks, as 
characterized by persistent NF-kB activity, excessive influx of neutrophils and macrophages, and 
massive granulation tissue in the stroma. In addition, the Pparg-knockout urothelium exhibited 
squamous metaplasia. The Krt14+ basal cell population, which is considered to be the cells of 
origin of bladder cancer, greatly expanded in the Pparg-deleted urothelium after infection, and 
some lesions progressed to acquire invasive features.  
Together these findings suggest that PPARG is essential for the normal differentiation of 
the urothelium and is a potent regulator of the inflammatory response after UTI. Understanding 
the link between the loss of PPARG, chronic inflammation and tumorigenesis in the urothelium 
could shed light on the urothelial differentiation network and pave the way for the development 
of therapeutic approaches to various urinary diseases.
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The urothelium is a stratified epithelium that serves as a crucial barrier between the urine 
and the inside of the body. It has an exceptionally high transepithelial electric resistance up to 
75,000 Ω/cm2 to prevent unregulated exchange of ions, metabolites, and toxic substances [1]. 
The urothelium lines the inner surface of the distal portion of the urinary tract, including the 
renal pelvis, ureters, urinary bladder, and prostatic urethra, with distinct features at each region 
[2]. In the bladder, the surface area is highly distensible in order to accommodate large changes 
in urine volume [3]. In addition to its role as a barrier, the urothelium actively regulates the 
passage of substances across the mucosal surface of the bladder [4]–[7]. Furthermore, the 
urothelium can sense external stimuli and release various mediators, which allow it to 
communicate information with adjoining cells and the underlying tissues. This enables an active 
response to changes in metabolism and in the environment by modifying ion and protein 
composition of the urine accordingly [8], [9]. 
 
1.1.1 Cell types of the urothelium 
The urothelium is comprised of three major cell types: umbrella cells, intermediate cells, 
and basal cells. 
Umbrella cells, or superficial cells, are highly differentiated cells that occupy the 
outermost layer of urothelium. They are large polyploid polyhedral cells that typically have 5-6 
sides and range from 25 to 250um in diameter, covering up to 50 underlying cells, hence the 
name umbrella cell [10]. Their shape changes according to the filling state of the bladder: 
cuboidal in the empty bladder and highly stretched and flat when the bladder is full [3]. Umbrella 
cells are responsible for the low permeability of the urothelial barrier [4], [11]. They are 
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specialized for synthesis and transport of a family of transmembrane proteins called uroplakins, 
which assemble into apical plaques, forming an asymmetric unit membrane (AUM) with an outer 
leaflet twice as thick as the inner leaflet [12], [13]. Discoidal or fusiform-shaped vesicles (DFV) 
are specialized in delivering and recycling uroplakins to and from the apical surface of the 
umbrella cells in response to filling and voiding of the bladder to expand and decrease apical 
surface area accordingly [14]–[16]. Approximately 90% of the apical membrane is covered by 
plaques, and the remaining surface is known as the hinge region [11]. The plaque regions are 
highly rigid and detergent insoluble while the hinge regions are relatively more flexible, giving 
the apical membrane a distinct scalloped appearance [17], [18]. Paracellular spaces between 
adjacent umbrella cells are sealed by high-resistance tight junctions, which effectively demarcate 
distinct apical and basolateral membrane domains in umbrella cells [19]–[21]. Urothelial tight 
junctions are comprised of tight junction protein 1 (zonula occludens,  ZO-1), occludin, claudin-
4, 8, and 12 [19], [22]. Just above the tight junction, interdigitations of apical membrane from 
adjacent cells zip the cell periphery [23]. The crystalline plaques combined with tight junctions 




















Figure 2.1 Ultrastructure of umbrella cells. (A) Discoidal or fusiform-shaped vesicles (DFVs). 
(B) asymmetric unit membrane (C) tight junctions. TJ: tight junctions, Ds: desmosomes (Figure 
modified from [24]) 
 
Intermediate cells are located below and in close proximity with umbrella cells. They are 
relatively few in number in murine urothelium [25]. Intermediate cells are often pyriform in 
shape, mono- or double- nucleated, and around 10–25 um in diameter [10]. Intermediate cells 
just beneath the umbrella cells are partially differentiated, which could enable them to rapidly 
differentiate when the overlying umbrella cells are dead and fallen off due to bacterial infection 
or exposure to toxins [26]–[28]. Some intermediate cells form long, thin cytoplasmic extensions 
that contact the basement membrane [3], [29]. 
 Basal cells are the largest population, comprising more than 80% of the urothelium in 
mice. Basal cells reside in both basal and suprabasal layers [25]. They are diploid and of regular 
size, approximately 5-10 um diameter [10]. Basal cells adhere to the basement membrane by 
hemidesmosomes mediated by beta4-integrin [24].  
 Different urothelial cell populations can be identified based on their expression of distinct 
sets of molecular makers. Cytokeratin-20 (KRT20) is solely expressed in the mature umbrella 
cells [30]. Uroplakins (UPK) are expressed by both umbrella and intermediate cells, but highly 
enriched in umbrella cells [25]. P63, a homologue of the P53 tumor suppressor gene, and sonic 
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hedgehog (SHH) are expressed in both intermediate and basal cells but are absent in umbrella 
cells [25], [31]. Cytokeratin-5 (KRT5) is specific to the basal cell population. Cytokeratin-14 
(KRT14) is expressed by a sub-population of the basal cells, which has been implied to be the 
progenitor population in the murine bladder [32], [33]. In addition, all urothelial cells express 
forkhead box A1 (FOXA1) and cytokeratin-7 (KRT7),  [30], [34] (Table 2.1). 
 
Table 1.1 
 KRT20 UPK P63 SHH KRT5 KRT14 
Umbrella cell + + - - - - 
Intermediate cell - + + + - - 
Basal cell - - + + + +/- 
Table 1.1 Markers for urothelial cells. 
 
1.1.2 Urothelial cell lineages  
The embryonic urothelium is derived from cloacal endoderm. The urothelium was 
initially thought to differentiate in a linear sequence as occurs in skin, starting from basal stem 
cells which progressively differentiate to intermediate cells then mature into umbrella cells [35]–
[38]. However, ongoing developmental studies in our lab discovered a transient population of 
progenitors P-cells (FOXA2+ P63+ KRT5- UPK-), which gives rise to intermediate and 
superficial cells between E12 and E14, and produce basal cells between E15-E17. Recent studies 
suggested that during homeostasis and acute injury, intermediate cells are responsible for 
producing new superficial cell daughters, wherease basal cells repopulate themselves. Basal cells 
only act as stem cells in response to chronic or repetitive damage, which depletes the 
intermediate cell population and causes robust inflammatory responses [25], [33]. It is unclear 
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which genetic or epigenetic pathways are altered in basal cells after repetitive damage, nor is it 
known whether these changes are triggered by inflammation. 
 
1.1.3 Uroplakins 
Uroplakins (UPK) are a family of transmembrane proteins that contribute to the 
formation of urothelial paques and asymmetric unit membranes (AUMs), which play an essential 
role in the permeability barrier function of the urothelium [39]. The uroplakin family is 
composed of at least five proteins: Uroplakins 1a, 1b, 2, 3a and 3b [40]. UPK1A and UPK1B 
both have four transmembrane domains (TMD) with a major and a minor hydrophilic domain 
extending extracellularly [41]. UPK2, UPK3A and UPK3B only have a single-span. UPK2 has a 
non-glycosylated N-terminal domain and a very small C-terminal domain [42]. UPK3A, on the 
other hand, has a heavily glycosylated N-terminal domain and possesses a significant C-terminal 
domain, which may be involved in anchoring urothelial plaques and/or transducing signals [43], 
[44]. UPK3B is the latest addition to the uroplakin family and seems to only play a minor role in 
the urothelium [45]. Overall, the massive extracellular domains of uroplakins compared to their 
cytoplasmic domains explain why the outer leaflets of the AUMs appear thicker.  
The four major uroplakins form two specific pairs: UPK1A/2 and UPK1B/3A 
heterodimers, which are required for their exit from the ER [46], [47].They further assemble into 
16nm hexagon crystalline AUM particles when they reach the apical membrane of umbrella 
cells, with six subunits arranged in inner and outer rings [13], [48]. A urothelial plaque contains 
approximately 1000–3000 AUM particles [24]. 
Uroplakins are essential for the barrier function of the urothelium. Upk3a knockout mice 
have a 70-80% reduction of urothelial plaques, partially compensated by Upk3b, and develop 
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hydronephrosis [49]. Knockout of the Upk2 gene results in a complete loss of urothelial plaques 
and a hyperplastic urothelium [50]. Both Upk3a knockout mice and Upk2 knockout mice have 
increased barrier permeability to water and urea [11], [51]. Altered uroplakin expression is also 
found in urothelial carcinoma [52]. 
Uroplakins are transported by discoidal or fusiform-shaped vesicles (DFVs), which are 
accumulated under and fuse with the apical surface of the umbrella cells in response to bladder 
filling through exocytosis and endocytosis [14]–[16]. DFVs are concentrated ~150-300nm below 
the apical membrane, stopped by a dense cytokeratin network including KRT20. The wall of this 
meshwork is perpendicular to the apical plasma membrane, forming parallel tunnels with tapered 
openings towards the apical membrane, guiding DFVs to the surface during bladder filling [30], 
[34]. Under hydrostatic pressure, the apical surface area of the umbrella cells could increase as 




Figure 1.2 Assembly of uroplakins. (a) Step-wise schema of uroplakin assembly into 
uroplaques. (b) the vesicular trafficking in umbrella cells. (Figure modified from [40])  
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1.1.4 Signaling pathways important in urothelial formation and regeneration 
 Communication between epithelial and stromal compartments is critical for urothelial 
specification, maintenance and regeneration.  
Proper urothelial differentiation relies on inductive signals secreted by urothelial cells 
and the underlying stroma. The role of retinoic acid, the active form of vitamin A, in maintaining 
urothelial phenotype has long been appreciated since vitamin A deficiency results in keratinizing 
squamous metaplasia in the urothelium and other epithelia [53]–[55]. Blocking retinoid signaling 
in the urothelium led to impaired umbrella cell formation during development and regeneration 
[25]. Fibroblast growth factor 7 (FGF7) is secreted by stromal cells and acts on urothelial cells 
through a paracrine manner to regulate urothelial stratification [56]. Mutations in the fibroblast 
growth factor receptor 3 (FGFR3) gene are prevalent in low grade urothelial tumors [57], [58]. 
Bone morphogenetic protein 4 (BMP4) and its receptor BMPR1A is another pair that is 
important for urothelial-stromal cross talk [28]. Knocking out Bmpr1a in the urothelium results 
in aberrant urothelial proliferation and failed umbrella cell differentiation after urinary tract 
infection [59].  
Likewise, the urothelium also sends reciprocal signals to influence the stroma. SHH 
pathway is essential for normal bladder development and regeneration. During development, 
SHH is expressed by the cloacal epithelia, while SHH-responsive cells are located in the peri-
cloacal mesenchyme, which later gives rise to bladder stroma. Abrogation of SHH signaling 
results in mesenchymal hypoplasia  [60], [61]. Release of SHH ligand has also been shown to be 
increased in injured urothelium, which is responsible for the upregulation of genes like Wnt2/4 
and Bmp4/5. This gene upregulation forms a feedback loop to stimulate stromal and urothelial 
proliferation and to promote urothelial differentiation [37], [62].  
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The differentiation state of urothelial cells also depends on their internal transcriptional 
network to integrate and react to signals from the microenvironment. Transcription factors that 
have been implicated in urothelial differentiation include FOXA1, PPARG, P63, E74-like factor 
3 (ELF3), and grainyhead like transcription factor 3 (GRHL3) [32], [63]–[66]. ELF3 has been 
identified as an early transcriptional regulator in the urothelium through analyzing short time 
series data. Knocking down ELF3 in normal human urothelial (NHU) cells results in reduced 
UPK3A expression as well as decreased transepithelial electrical resistance [65]. FOXA1 is 
important in maintaining urothelial phenotype. Loss of FOXA1 in the urothelium leads to 
urothelial hyperplasia in male mice and keratinizing squamous metaplasia in female mice [32]. 
PPARG activation has been associated with urothelial differentiation. Treating urothelial cells 
with PPARG agnoist reverses squamous metaplasia and induces uroplakin expression [64], [67]. 
GRHL3 is essential for terminal differentiation of umbrella cells. Ablation of GRHL3 results in 
failure of apical membrane specialization [68]. P63 is important in maintaining the progenitor 
states of the cells. The urothelium of P63-null mouse embryos is comprised by a single layer of 
cuboidal-shaped UPK3A expressing cells without intermediate or basal layers [63].  
 
1.2 Urinary Tract infection (UTI) 
Urinary tract infection is one of the most common bacterial infections worldwide. 
Around 150 million people develop UTIs each year and the number has been increasing steadily, 
partially attributed to a rise in the elderly population and the use of indwelling urinary catheters. 
[69], [70]. Around half of women and 5% of men will experience at least one UTI during their 
life time, and 25% of women will suffer from recurrent UTIs within 6 months of their first 
episode [71], [72]. Current treatments for UTI faces serious challenges from the rise of 
 10 
multidrug-resistant uropathogenic bacteria and from the limitation that antibiotic therapy does 
not preclude recurrences [73], [74]. New discoveries on the fundamental biology of UTIs could 
provide new insights for developing alternative therapeutic approaches.  
 
1.2.1 Uropathogenic Escherichia coli (UPEC) 
 A number of microbes can cause UTI, but uropathogenic Escherichia coli, which usually 
originates from the gut, accounts for more than 80% of infections [69]. UPEC expresses FimH 
adhesin at the distal tip of hair-like organelles called type 1 pili, which is critical for its 
attachment and invasion [75]. FimH can bind to mannosylated receptors on the umbrella cells, 
primarily UPK1A [76]. Attached bacteria then invade into umbrella cells by hijacking the innate 
vesicular trafficking system designed for accommodating the change in bladder volume [77]. 
Once UPEC is internalized into the cytoplasm, they are protected from expulsion by urination or 
infiltrating phagocytes [78]. Successfully invaded UPEC then initiates intracellular growth and 
the mass later mature into biofilm-like foci designated intracellular bacterial communities 
(IBCs). Bacteria within the IBCs periodically detach and flux the host cell to initiate another 
round of infection [75], [79], [80]. Those bacteria acquire a filamentous morphology, which may 
















Figure 1.3 UPEC pathogenic cycle. UPEC binds to UPK1A expressing umbrella cells and 
subsequently invades into the cytoplasm by harnessing the cycling vesicles for trafficking apical 
membrane segments. Intracelluar UPEC develops IBCs, from which a subset of bacteria detach 
and reemerge for a second round of infection. Eventually a quiescent reservoir is formed, which 
could contribute to the recurrence of infection, although the trigger of the reemergence is 
unkown. (Figure taken from [75])      
 
1.2.2 Host defense 
 Most of the time, UTIs are contained within the tract and resolves within days even 
without treatment [83]. This resistance is largely attributed to the robust innate immune defense 
in the bladder, whereas the adaptive immune responses are limited [78]. 
The urothelium is the first line of defense against UPEC infection. Urothelial cells 
continuously secret antimicrobial peptides and other factors to inhibit bacterial growth in the 
urine [78]. Host responses in the umbrella cells are triggered upon UPEC attachment. FimH 
binding induces major conformational changes in the uroplakin proteins and subsequently 
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activate intracellular signaling pathways [76], [84]. Internalized UPEC can be detected by toll-
like receptor 4 (TLR4) or mucolipin 3 (TRPML3), which then activate pathways that direct 
exocytosis of UPEC-containing vesicles, expelling bacteria back to the lumen in a matter of 
minutes [85], [86]. The invasion of bacteria also triggers an apoptotic response in the umbrella 
cells and results in exfoliation of this layer [87]. Sloughing IBC-containing cells into urine and 
excreting them from the body help eliminate thousands of bacteria. Studies in mouse models 
have shown that there are shedded umbrella cells in the urine 6 hours after transurethral 
inoculation of UPEC [28]. Furthermore, pattern recognition receptors, like TLR4, trigger 
inflammatory responses by activating the NF-kB pathway, which in turn initiates the production 
of pro-inflammatory cytokines and chemoattractants, such as interleukin (IL) -1, -8 and tumor 
necrosis factor (TNF) [88]. These inflammatory mediators result in a vigorous influx of immune 
cells to the bladder to counter the bacterial challenge. 
Innate immune responses play a major role in defending against UPEC and an array of 
proinflammatory cytokines and chemokines have been identified to be upreagulated over the 
course of UTI. These include IL1B, IL6, IL17, granulocyte colony-stimulating factor (G-CSF) 
and keratinocyte-derived cytokine (KC). Most of the mediators reach their peak expression level 
24 hours post infection and then decrease over time to baseline 2 weeks after infection [89]. 
The first immune cells to get recruited by this inflammatory milieu are neutrophils, which 
are present in urine as early as 2 hours post-infection, and their numbers peak by 6 hours in 
mouse models [90]. Massive neutrophil infiltration is a diagnostic hallmark of UTI and the 
number of neutrophils closely correlates with the bacterial load in the urinary tract [91], [92]. 
Neutrophils play a predominant role in antibacterial defense in the bladder through their 
phagocytic ability as well as the release of an array of cytotoxic products [93]. Blocking 
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granulocyte infiltration to the bladder by GR1 antibody resulted in poor bacteria clearance [91]. 
However, neutrophil influx is a double-edged sword. Excessive neutrophil responses could cause 
substantial damage to the bladder tissue as they release cytotoxic products and break through cell 
junctions between adjoining urothelial cells, predisposing the bladder to worse infection 
outcomes [94], [95]. Consistent with this, neutralization of granulocyte colony-stimulating factor 
(CSF3), a pro-inflammatory cytokine inducing neutrophils emigration from the bone marrow 
into the blood stream, decreases neutrophil recruitment to the bladder after UTI and resulted in a 
lower bacterial load [89].  
Macrophages, another kind of phagocytes, play a central role in modulating the innate 
immune defense against UPEC infection. Tissue-resident macrophages are present in the bladder 
stroma and responsible for immune surveillance during homeostasis. Upon infection, resident 
macrophages produce pro-inflammatory cytokines to recruit other immune cells and coordinate 
their activities [78], [96]. It has been shown that inflammatory macrophages recruited from the 
periphery by resident macrophages are essential for neutrophil migration across the basement 
membrane to reach bacteria in the urothelium [97]. After bacteria clearance, macrophages are 
considered as the major cell type that is responsible for promoting resolution of inflammation by 
producing anti-inflammatory cytokines as well as phagocytizing apoptotic neutrophils, as 
observed in other organs [96], [98], [99]. However, the function of macrophages in the resolution 
phase has not yet been demonstrated specifically in the bladder. Studies show mast cells may 
also have similar roles to macrophages in response to UPEC infection [100]. One study showed 
that IL10, a major inhibitor of the proinflammatory immune response, was produced by mast 
cells 6 hours post infection [101].  
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γδ T cells, a distinct T cell sub-population has been considered to be a bridge between the 
innate and adaptive immune system, have an intriguing role in the bladder upon UPEC infection 
[102]. Investigating genetic knockout mice revealed that mice without γδ T cells are more 
susceptible to UTI, suggesting γδ T cells are important for defending against UPEC infection 
[103]. Further studies showed that γδ T cells are the main source of IL17 in the bladder. IL17 has 
been shown to be critical for autoimmune disease and in bacterial infection, which spans both the 
innate and adaptive arms of the immune system. IL17 deficiency leads to defects in bacterial 
clearance after UTI, suggesting it contributes to the innate immune defense. Interestingly, IL17 
does not appear to contribute to the adaptive immune response after UPEC infection, suggesting 
γδ T cells mainly participate in innate responses after UTI [104].  
Adaptive immune responses are considered limited in response to infections explicit in 
the bladder. But some evidence suggests that the adaptive immune response also participates in 
defending against UPEC, although the data remains controversial. Immunization with FimH-
adhesin-based systemic vaccines inhibits UPEC colonization in the bladder, suggesting humoral 
immunity plays a role [105]. However, examination of urine specimens from acute cycstitis 
patients failed to detect an antibody response, raising the question wthether humoral immune 
responses are naturally evoked by UPEC infections in the bladder [106]. Potential cellular 
responses to UPEC infection has been studied using an engineered UPEC strain which expresses 
ovalbumin (OVA) as an antigenic marker [107]. However, when OVA is introduced into the 
urothelium, it could also serve as a foreign antigen, and this study did not address the question of 
whether the cellular response is specific for UPEC or for OVA. Recent studies showed that 
macrophages and mast cells contribute to muting adaptive immune response during UTI. It has 
been showed that depletion of resident macrophages improves bacteria clearance after a second 
 15 
infection, and the effect is lost in mice depleted of T cells [108]. Another study showed that mast 
cell derived IL10 decreased the activation of dendritic cells and in turn tempered adaptive immne 





Figure 1.4 Host responses to UPEC infection in the bladder. (Figure taken from [109]) 
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1.2.3 Regeneration of the urothelium 
 The urothelium is one of the most quiescent epithelium in the body, with a turnover rate 
about 3-6 months [110]. However, the urothelium can regenerate rapidly in response to acute 
injury such as UTI. 
Exfoliation of umbrella cells triggered by UPEC attachment and invasion results in 
disrupted barrier function and gives UPEC and other toxic substances access to the underlying 
tissue. To minimize the harmful effects, the quiescent urothelium promptly shifts to a rapid 
regenerating state. Intriguingly, the expression of genes involved in urothelial proliferation and 
differentiation, such as Elf3 and delta-like 1(Dll1), has already changed within 1.5-3 hours of 
infection,  prior to umbrella cell exfoliation [28], [111]. Urothelial proliferation starts around 12 
hours post infection, peaks at 24 hours, and ceases around 72 hours [37]. After 7 days, the 
urothelial barrier is restored, except some of the newly generated umbrella cells are smaller in 
size [28]. By 2 weeks, the urothlium is completely repaired itself.     
 
1.3 Peroxisome proliferator-activated receptors (PPARs)  
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone 
receptor superfamily, which play central roles in regulation normal biological processes and 
diseases. The term peroxisome proliferator-activated receptor came from the observations that 
PPARs bind to peroxisome proliferator and are responsible for their effects in modulating gene 
expression and peroxisomes proliferation [112]. Peroxisomes are organelles essential for 
breaking down fatty acids and generating reactive orxgen and nitrogen species. Its function of β-
oxidation is inducible by peroxisome proliferators [113]. There are three PPAR genes in this 
family: PPARA, PPARD, and PPARG [114]. They are expressed in a broad range of tissues and 
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exert multiple functions involved in energy metabolism and storage, inflammation, cellular 
differentiation, and other important biological processes [115]. 
PPARs share a similar structure with four major functional domains: A N-terminal 
domain (A/B), a DNA binding domain (DBD), a hinge region, and a C-terminal ligand binding 
domain (LBD). The A/B domain harbors a ligand-independent transactivation domain AF-1 
(activation function 1) at its extreme N-terminal region. The DBD is formed by two zinc finger-
like motifs and highly conserved. The LBD could bind a variety of ligands and incorporates a 
ligand-dependent transactivation domain AF-2 (activation function 2) at its C-terminus, which is 
responsible for the interaction with other co-factors [115]. The specificity of the three PPARs to 
target genes is in part determined by their AF-1 domain. Deletion of the N-terminus leads to 




Figure 1.5 Domain structure of PPARs. PPARs contain a A/B domain, a DNA-binding domain 
(DBD), a hinge region and a ligand-binding domain (LBD). (Figure modified from [117] ) 
 
PPARs can regulate gene transcription by different mechanisms. PPARs can serve as 
ligand-activated transcription factors that form heterodimers with RXR. The non liganded form 
of the PPAR/RXR heterodimer normally resides in the cell nucleus and binds to DNA response 
elements in the promoter region of target genes designated as peroxisome proliferator response 
elements (PPREs). PPREs are consensus sequences containing a direct repeat of AGGTCA, 
separated by one or two nucleotides (DR-1 or DR-2) [115]. The heterodimer complex is kept 
inactive by corepressor complexes comprised by components such as nuclear receptor co-
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repressor 2 (NCOR2), which possesses histone deacetylase (HDAC) activities to maintain a 
tightly packed structure of chromatin, and therefore repress gene transcription [118], [119]. 
Ligand binding induces a conformational change of the LBD of PPARs, which leads to an 
affinity switch that releases corepressors and recruits coactivators [120]. Numerous coactivators 
have been identified, including PPARG coactivator 1-α (PPARGC1A), CREB-binding protein 
(CREBBP) and E1A binding protein p300 (EP300), which are responsible for chromatin 
modification. Acetylation of histone proteins relieves the tight chromatin structure and open it up 





Figure 1.6 The interactions of PPARs with corepressors and coactivators. PPAR/RXR 
heterodimer is kept inactive in the unliganded state by corepressor complexes. Ligand binding 
releases corepressors and recruits coactivators to remodel the chromatin structure, which gives 
RNA polymerase II complex access to the promoter region of target genes for transcription. 
(Figure taken from [121]) 
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PPARs can also repress gene transcription by transrepression, which is independent of its 
DNA binding ability but through interacting with other transcription factors at protein level 
[122]. For instance, PPARs could bind directly with nuclear factor-κB (NF-κB) and sequester 
their activities by preventing their binding to DNA and exporting them back to cytoplasm for 
degradation [123]–[125]. Alternatively, PPARs could compete with other transcription factors 
for an overlapping though limiting set of coactivators [126]. In addition, it has also been 
suggested that PPARs could interfere with the clearance of corepressors of other transcriotion 




Figure 1.7 Mechanisms of PPAR-mediated transrepression. PPARs could interfere other 
pathways by direct interactions with other transcription factors to (a) prevent their binding to DNA, 
(b) shuttle their back to cytosol, (c) target them for degradation, by (d) competing for shared 




PPARG exists in two isoforms, PPARG1 and PPARG2, both encoded by the same gene 
but utilizing two distinct promoter and alternate splicing, hence PPARG2 harbors 30 additional 
amino acids at its N-terminus [130]. PPARG2 is exclusively expressed in adipose tissue [131], 
whereas PPARG1 is expressed in several other tissues in addition to fat, including muscle, 
intestine, kidney, and immune cells [132]–[136]. 
 
1.4.1 PPARG ligands 
A vast number of natural and synthetic ligands could bind to PPARG. Natural ligands for 
PPARG include polyunsaturated fatty acids, arachidonate metabolites, eicosanoids and certain 
prostanoids such as 15-deoxy-Δ12, 14-prostaglandin J2 (15-dPGJ2) [137]. Various natural 
compounds can bind PPARG at a micromolar level, but in vivo they usually are present in a 
much lower level. Whether it is sufficient to activate PPARG remains unclear [138]. Despite 
intensive research efforts, the identification of specific endogenous PPARG ligand turns out to 
be difficult, and raises the question whether PPARG has one highly specific ligand or if it is 
activated by the combined concentration of a set of weakly activating fatty acids and their 
derivatives. In contrast, synthetic agonists, such as thiazolidinediones (TZDs), are potent PPARG 
activators. Members of the TZD family like troglitazones, rosiglitazone and pioglitazone have 
been used for treating type 2 diabetic patients [129], [139]. Synthetic antagonists include 
bisphenol A diglycidyl ether 7 (BADGE), nitrobenzanilide 9 (GW9662) and nitrobenzanilide 10 




1.4.2 The function of PPARG in different tissue 
Adipose tissue 
PPARG was initially identified as a receptor that regulates adipogenesis. Indeed, PPARG 
plays a critical role in promoting adipocyte differentiation and maturation while suppressing 
osteogenesis [141]. Knocking down Pparg in 3T3-L1 cells, a preadiopcyte cell line, suppresses 
their differentiation to adipocyte, whereas ectopic expression of Pparg in NIH 3T3 cells, a 
fibroblast cell line, in combination with PPARG agonist treatment, is sufficient to stimulate 
adipose differentiation of the fibroblast cells [142], [143]. Examination of Pparg-null mice 
revealed that all types of adipose tissue are absent [144]. These observations provided direct 
evidence that PPARG is indispensatble for adipogenesis both in vitro and in vivo. Lineage 
tracking studies of PPARG expressing cells in the adipose tissue uncovered an adipogenic 
progenitor population residing in the adipose vasculature compartment. Treating those cells with 
TZD promoted their proliferation and differentiation. However, long-term TZD treatment 
resulted in exhaustion of the progenitor pool, suggesting that over activation of PPARG could 
also lead to deleterious consequences [145].  
A number of genes involved in lipid metabolism and adipogenesis are regulated by 
PPARG, such as lipoprotein lipase (Lpl), acyl-CoA synthetase (Acsl), and fatty acid binding 
protein 4 (Fabp4) [115]. It has been shown that PPARG cooperates with CCAAT/enhancer-
binding protein alpha (CEBPA) to form a positive feedback loop and promote the adiopogneic 
program [143], [146].  
In addition, PPARG controls lipid homeostasis and its activation increases insulin 
sensitivity in adipose tissue. TZD treatment can efficiently alleviate insulin resistence induced by 
a high-fat diet, but the effect is lost in mice with adipose-specific Pparg knockout [147].  
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PPARG activation improves insulin sensitivity at several levels. First of all, PPARG directly 
modulates adipocyte lipid intake through upregulating the expression of fatty acid transport 
proteins, which facilitate the entry of free fatty acids into adipocytes, therefore lowering their 
circulating levels [148]. Secondly, PPARG promotes the storage of FFAs in adipocytes by 
increasing the expression of phosphenolpyruvate carboxykinase (PCK1), which is essential for 
triglyceride synthesis [149]. Moreover, PPARG regulates the production of numerous 
adipokines, including adiponectin (ADIPOQ), resistin (RETN), TNF and IL6, all of which have 
been implicated in insulin resistance [150].  
 
Immune cells 
 PPARG plays critical roles in various immune cells. Its function is most well-studied in 
macrophages and dendritic cells.  
In macrophages, PPARG has been implicated for its role in regulating the lipid intake by 
macrophages from the circulation. CD36, the scavenger receptor on macrophage, is a direct 
target of PPARG [151]. PPARG is also essential for macrophage intracellular lipid metabolism 
[152], [153]. Deletion of the Pparg gene in macrophages causes remarkable reduction of gene 
expression involved in cholesterol flux, including Cd36, Lpl and Abcg1, resulting in higher lipid 
concentration in the blood [154]. Moreover, PPARG has been demonstrated as a master regulator 
of macrophage polarization. Activating PPARG in macrophages downregulated the production 
of pro-inflammatory cytokines such as TNF and IL6 while upregulating the production of anti-
inflammatory cytokines like IL10, shifting the macrophages from M1 phenotype to M2 
phenotype [155]. 
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In dendritic cells (DCs), PPARG activation has an effect on their differentiation and 
maturation. Activation of PPARG during DC differentiation changes the expression pattern of 
cell surface receptors of DCs, including down-regulation of CD1A1 and CD80 expression and 
up-regulation of CD86 expression. Challenging those cells with lipopolysaccharides (LPS) 
resulted in reduced cytokine production including IL10, IL12 and IL15, suggesting PPARG 
activation inhibits DC maturation [156]. Furthermore, PPARG in DCs modulates the T-
helper1/T-helper2 (Th1/Th2) balance via regulating the production of cytokine and chemokine in 
DCs. Activation of PPARG in immature human monocyte-derived dendritic cells resulted in a 
dramatic decrease of IL12 secretion, a Th1 promoting cytokine, after stimulated the cells with 
LPS. In addition, PPARG also reduced the secretion of C-X-C Motif Chemokine Ligand 10 
(CXCL10) and C-C Motif Chemokine Ligand 5 (CCL5) from DCs, both of which are involved 
in the Th1 cell recruitment [157].  
 
Placenta 
PPARG is required for placental development. Deficiency of PPARG leads to embryonic 
death at E10.5 due to placental abnormalities, including small labyrinth, decreased number of 
spongiotrophoblasts, and expanded giant cell layers [138], [144]. Further studies demonstrated 
that PPARG contributes to both maintenance of undifferentiatied trophoblast and differentiation 
towards the labyrinthine lineages. Knockout of Pparg in trophoblast stem (TS) cells resulted in 
reduced proliferation of TS cells and premature differentiation towards trophoblast giant cells at 
the expense of synctiotrophoblasts [158]. Direct targets of placental PPARG include Muc1, 
which is critical in forming protective mucous barriers on epithelial surfaces, and Cgb5, a 




Increasing amount of data imply that PPARG promotes cellular differentiation and 
regulates inflammatory responses of several epithelia.  
In the lung, ablation of Pparg specifically in the airway epithelium led to insufficient 
lung maturation and abnormal lung structure and physiology [160]. Further challenging the 
Pparg-deleted lung with chronic cigarette smoke resulted in excessive macrophage accumulation 
in the lung and elevated levels of chemokines, including CCL5, CXCL10 and CXCL15, which in 
turn increased the susceptibility to emphysema [161]. In accordance with this result, another 
study reported that treating human lung epithelial cells with PPARG agonists decreased the 
expression of cytokine-induced inflammatory mediators [162].  
In the gut, PPARG collaborates with Hic-5 to promote terminal specialization of 
intestinal epithelial cells [163]. Ablation of Pparg in the colon epithelium in vivo results in 
increased susceptibility to inflammatory bowel disease [164]. In contrast, treatment of PPARG 
agonists prior to intestinal ischemia-reperfusion reduced injury by downregulating TNF and 
ICAM1 expression and reducing neutrophil infiltration [165], [166]. Similarly, in Caco-2 cells, a 
human colon cancer cell line, it has been shown that PPARG attenuates inflammation through 
antagonizing the function of NF-kB, a pro-inflammatory transcription factor, by exporting the 
RELA subunit of NF-kB complex from the nucleaus to cytoplasm [124].  
  
1.4.3 PPARG in the urothelium 
PPARG expression can be detected as early as embryonic day 13.5 in mice and has been 
suggested to promote the differentiation of the urogenital sinus into mature urothelium [167]. 
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 The Southgate group has studied PPARG functions in normal human urothelial (NHU) 
cell from the ureters for years using PPARG agonists and antagonists [64], [67], [168]–[170]. 
They found that treating cultured NHU cells with a PPARG agonist in combination with an 
EGFR inhibitor reverses squamous metaplasia and promotes urothelial differentiation [64], [67]. 
In this in vitro system, PPARG activation induces uroplakin expression through intermediary 
transcriptional regulators such as forkhead box A1 (FOXA1) and interferon regulatory factor-1 
(IRF-1). Potential FOXA1 and IRF-1 binding sites have been identified in the promoter regions 
of UPK1A, 1B, 2 and 3A, and knocking down FOXA1 and IRF-1 abolishes PPARG agonist 
induced urothelial differentiation [170]. Moreover, PPARG and EGFR pathways have been 
implicated in the regulation of tight junction formation in NHU cells, another integral part of 
urothelial differentiation. Activating PPARG and blocking EGFR shift the cells from expressing 
a proliferation-associated profile of claudin to a more differentiation-associated profile including 
claudin 3, 4 and 5 [169].  
 Gene expression profiling of bladder cancer samples revealed that PPARG is involved in 
the development of bladder cancer, but its function still remains unclear. Since PPARG 
activation can promote urothelial differentiation, it is not surprising that early research showed 
that PPARG agonist treatment led to tumor growth arrest in several bladder cancer cell lines, and 
that PPARG expression level is inversely correlated to the stage and grade of bladder cancer 
[171]–[175]. However, PPARG has also been implicated in promoting bladder tumorigenesis in 
other studies. Thiazolidinediones or TZDs, which are synthetic agonists for PPARG,  were used 
for treating patients with type 2 diabetes but have been withdrawn from the market by several 
countries due to an increased risk of bladder cancer [174]. Several PPARG and dual PPARA/G 
agonists were listed as having carcinogenic activities in the bladder of rats [176]. Genetic 
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analysis of bladder cancer cells revealed a significant increase in PPARG gene copy number, 
which is positively correlated to cancer cell migration and invasive ability [177], [178]. 
 Whole-genome analyses of muscle-invasive bladder cancer (MIBC) in recent years 
revealed its heterogeneous nature. MIBC could be roughly grouped into luminal and basal 
subtypes. Luminal subtype expresses high level of UPK, KRT20 and other low molecular weight 
keratins that are enriched in umbrella cells, has elevated FGFR3 activation via copy number gain 
or translocation which results in a FGF3-TACC3 fusion protein, and is enriched with papillary 
morphology. Basal subtype highly expresses high molecular weight keratins including KRT5, 
KRT6A, KRT6B and KRT14, which are more abundant in basal cells, and is enriched with 
squamous features. Intriguingly, PPARG expression is elevated in luminal tumors, of which over 
15% also has an increase in PPARG gene copy number, whereas PPARG expression is 
significantly downregulated in basal tumors [179]–[183]. The discovery of intrinsic 
heterogeneity of bladder cancer serves as a starting point to reconcile the conflicting results from 
the past.   
 The function of PPARG in the luminal type of tumors has been further examined in vitro. 
Activating PPARG turned on other luminal transcriptional pathways, suggesting PPARG plays a 
central role in controlling luminal biomarker expression [181]. The exact contribution of PPARG 
in the basal subtype is less clear. Expression profiles showed that PPARG-regulated lipid 
metabolic genes are significantly down-regulated in squamous cell carcinoma-like tumors and in 
vitro studies found deficiency of PPARG in combination of PTEN drove keratinizing squamous 
metaplasia[184], [185]. Moreover, low PPARG activity has been observed in claudin-low 
subtype of bladder tumors, where it has been implicated as the cause of unrestraint NF-kB 




The urothelium is severely understudied and our knowledge of its differentiation and 
maintenance lags far behind studies in other epithelium. Understanding the transcriptional 
network that regulates barrier formation in the bladder will provide insights for a variety of 
urinary diseases caused by a compromised barrier. Increased attention has been drawn to PPARG 
for its therapeutic potential for bladder cancer and other diseases. A deeper understanding of its 
actions in the urothelium is required to further advance the development of PPARG agonists for 
therapeutic use while avoiding undesired side effects. The experiments in this study were 
designed to explore the function of PPARG in urothelial formation and regeneration in vivo, in 
an effort to further connect the transcriptional network in urothelial differentiation. By using 
novel mouse models, this study will also contribute to bridge the gap between in vitro studies 







Chapter 2  





2.1 Mouse strains and genotyping 
Experiments were performed according to protocols approved by the Institutional Animal 
Care and Use Committee of Columbia University. Mice were maintained under specified 
pathogen-free conditions in a barrier facility and under a 12-hour light cycle. All mouse lines 
carried on a Swiss Webster background. ShhCre, Up2CreERT2 and mTmG mice were obtained from 
the Jackson Laboratory. K5CreERT2 mice were obtained from D. Metzger and P. Chambon at the 
IGBMC, France. Pparg floxed mice were generated in the Gonzalez laboratory (UCSD). All 
mouse lines used in this study are listed in Table 2.1. 
Genotyping was done by PCR of the tail using a PCR Mastercycler pro (Eppendorf). 
Genotyping primers are listed in Table 2.2 and PCR programs used are listed in Table 2.3. 
 
Table 2.1 


















(stock # 007576) 
[190] 




Table 2.2  





5’- GCGGGAGTTCCAGAAAGA G-3’ WT band: 338bp 
5’-AGGACAGCCAGCAGAATCAG-3’ 






5’-CTCCAATGTTCTCAAACTTAC-3’ WT band: 250bp 
Flox band: 285bp 5’- GATGAGTCATGTAAGTTGACC-3’ 
mTmG 
5’- CTCTGCTGCCTCCTGGCTTCT-3’ WT band: 250bp 
5’- CGAGGCGGATCACAAGCAATA-3’ 
5’- CTCTGCTGCCTCCTGGCTTCT-3’ Mut band: 250bp 
5’-TCAATGGGCGGGGGTCGTT-3’ 










 Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 
ShhCre 95℃ 94℃ 60℃ 72℃ Repeat step 2-4 for 40 cycles 72℃ 
5min 30s 30s 45s  7min 
Up2CreERT2 94℃ 94℃ 65℃ 68℃ Repeat step 2-4 for 10 cycles 94℃ 
2min 20s 15s 10s  15s 
K5CreERT2 94℃ 94℃ 55℃ 72℃ Repeat step 2-4 for 35 cycles 72℃ 
5min 30s 30s 30s  7min 
Pparg 94℃ 94℃ 60℃ 72℃ Repeat step 2-4 for 40 cycles 72℃ 
6min 1min 30s 30s  7min 
mTmG 94℃ 94℃ 58℃ 72℃ Repeat step 2-4 for 35 cycles 72℃ 
3min 30s 1min 1min  2min 
Table 2.3 PCR programs for genotyping 
 
2.2 Histological and immunofluorescence analysis 
Bladders were dissected in PBS then fixed in either 4% paraformaldehyde (PFA) or zinc 
fixative overnight at 4℃ on a horizontal shaker. Following fixation, bladders were transferred to 
70% ethanol and stored at 4℃ until paraffin embedding. Paraffin blocks were sectioned at 5um 
thickness using RM2125 RTS Microtome (Leica), then dried on a slide warmer (Fisher 
Scientific) overnight or in 37℃ incubator for several days. Sections were stained with 
Hematoxylin and Eosin (H&E) for histology analysis. 
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For immunofluorescence staining, slides were deparaffinized in histoclear for 10min 
twice, then dehydrated by washing 10min in 100% ethanol twice, 10min in 95% ethanol twice, 
then 10min in running water. For antigen retrieval, depending on the antibody used, one of the 
following methods was performed: 1) boiling the slide in PH6 buffer for 30min, 2) boiling the 
slides in PH9 buffer for 15min, 3) treating the section with 0.1ug/ml proteinase K solution for 
1min followed by boiling in PH6 or PH9 buffer for 10min, 4) treating the section with 0.1% 
trypsin for 1min followed by boiling in PH6 or PH9 buffer for 10min. After boiling, slides were 
cooled for around 40min before transferred to 1xPBS/0.3% Triton X-100 for 20min to 
permeabilize the tissue. Then slides were incubated in 10% horse serum in 1xPBS/0.3% Triton 
X-100 for 1 hour. Primary antibodies were diluted in 1xPBS/0.3% Triton X-100 with 1% horse 
serum as specified in Table 2.4. 150ul primary antibody cocktail was applied to each slide. The 
slides were incubated overnight in dark moisture chamber at 4℃. The following day, excessive 
primary antibodies were washed out by washing the slides 10min in 1xPBS for three times. 
Secondary antibodies (Jackson Immunoresearch) were diluted 1:700 in 1xPBS/0.3% Triton X-
100 with DAPI. 150ul secondary antibody cocktail was applied to each slide and left on for 30-
120 min at room temperature. Excessive secondary antibodies were washed out by washing the 
slides 10min in 1xPBS for three times. Then sections were mounted and imaged using Zeiss 
Axiovert 200M with Apotome. 
 
Table 2.4 
Antigen Supplier Cat# Host species Dilution 
α-SMA Sigma C6198 Mouse 1:300 
CD3 abcam Ab11089 Rat 1:50 
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CD19 eBioscience 14-0194-80 Rat 1:100 
CD45 BDsciences 550539 Rat 1:50 
E-Cadherin R&D system AF748 Goat 1:400 
E.coli USBiological E3500-10 Rabbit 1:300 
F4-80 ebioscience 14-4801-82 Rat 1:100 
GRHL3 Aviva ARP33196 Rabbit 1:100 
KRT1 abcam Ab24643 Rabbit 1:200 
KRT5 Biolegend 905901 Chick 1:500 
KRT5 Biolegend 905501 Rabbit 1:500 
KRT10 Santa cruz Sc-53252 Mouse 1:500 
KRT13 LSBio LS-B10431 Rabbit 1:400 
KRT14 BioGenex MU146-5UC Mouse 1:50 
KRT14 Biolegend 906001 
 
Chick 1:500 
KRT14 Biolegend 905301 Rabbit 1:300 
KRT20 Dako M7019 Mouse 1:200 
Ki67 abcam Ab15580 Rabbit 1:200 
Laminin Sigma L9393 Rabbit 1:100 
NF-kB p65 abcam Ab19870 
 
Rabbit 1:300 
p63 GeneTex GTX102425 Rabbit 1:400 
p63 R&D system AF1916 Goat 1:200 
PPARG Santa cruz sc-7273 Mouse 1:100 
PPARG Cell signaling technology 2435 Rabbit 1:100 
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pSTAT3 Cell signaling technology 9145 Rabbit 1:200 
SNAIL+SLUG abcam Ab180714 Rabbit 1:200 
UPK1A Gift from Sun lab  Mouse 1:200 
UPK1B Gift from Sun lab  Mouse 1:100 
UP2 Santa Cruz sc-15178 Goat 1:50 
UPK3 santa cruz sc-15186 Goat 1:200 
UPK3 Fitzgerald 10R-U103a Mouse 1:50 
Table 2.4 Primary antibodies used in this study 
 
2.3 Transmission electron microscopy 
Bladders were dissected in 0.1M Phosphate Buffer (PB) then fixed in 4% glutaraldehyde 
overnight at 4℃ on a horizontal shaker. The following day, bladders were washed in PB 
thoroughly then transferred to 1% osmium tetroxide. After the tissue turned black, the bladders 
were dehydrated through increasing concentrations of ethanol (from 70% to 100%). Then the 
bladders were incubated in propylene oxide (PO) for 15min. The bladders were transferred to 
PO:Epon 1:1 mixture and left overnight at room temperature to allow PO evaporate. The Epon 
was replaced daily for the following two days. Then the bladders were placed into BEEM™ 
capsules and filled with fresh Epon. The samples were incubated at 60℃ for 3 days to harden. 
Then the blocks were sectioned and imaged by transmission electron microscopy.  
 
2.4 RNA-seq 
Bladders were dissected in OPTI-MEM media, cut open from the neck to the dome, then 
transferred to 20mM EDTA solution in PBS and incubated for 20min to loosen the urothelium 
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from the stroma. Bladders were transferred to fresh OPTI-MEM media and the urothelium were 
manually scrapped off from the stroma. The media containing urothelial cell patches was 
collected and spinned down at 500 xg for 5min at 4℃ (Eppendorf Centrifuge 5417C). The 
supernatant was discarded and the pellet was processed for total RNA extraction. 
Only samples having a total amount more than 100ng and a RIN>8 were used for RNA-
seq. mRNA were enriched using poly-A pull-down before proceed for library preparation using 
Illumina TruSeq RNA prep kit. Libraries were then sequenced using Illumina 
HiSeq2500/HiSeq4000 at Columbia Genome Center. 30 million of single-end 100bp reads were 
acquired per sample.  
Sequencing data were processed by RTA (Illumina) for base calling and bcl2fastq2 
(version 2.17) for converting BCL to fastq format, coupled with adaptor trimming. Then the 
reads were mapped to Mouse: UCSC/mm10 as reference genome using STAR(2.5.2b) and 
featureCounts(v1.5.0-p3). Differentially expressed genes were identified using DEseq, an R 
package based on a negative binomial distribution that models the number reads from RNA-seq 
experiments and test for differential expression. 
Differentially expressed genes were filtered by average expression level (FPKM) greater 
than 10, differential expression greater than 2 fold, and adjusted p-value less than 0.05 by 
Benjamini-Hochberg multiple testing correction. GO categories were obtained with q-value less 
than 0.05 by Benjamini-Hochberg multiple testing correction. 
 
2.5 Dye-retention assay 
Female adult mice were induced voiding to empty their bladders before anaesthetized 
using isoflurane. Then the animals were catheterized using a PE10 tube to instill 200ul of 0.1% 
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methylene blue in 0.9% NaCl [49]. The animals were maintained under anesthesia for 20min 
before sacrifice. The bladders were harvested and washed extensively in 0.9% NaCl solution. 
Bladders with mechanical damage to the lining were excluded. The retained dye in the bladders 
was extracted by 1ml chloroform per sample at 50℃ overnight, and its concentration was 
measured at OD 660 nm.  
 
2.6 Tamoxifen administration 
For Up2CreERT2; Ppargfl/fl  line, adult mice (> 8 weeks old) were injected with 5mg 
tamoxifen intraperitoneally three times over a period of 7 days. For K5CreERT2; Ppargfl/fl line, 
neonatal pups were injected with 0.7mg tamoxifen subcutaneously at postnatal day 2. 
 
2.7 Bacterial culture and experimental bladder infection 
UTI89, a type 1-fimbriated uropathogenic E. coli (T1F-UPEC) isolate from an acute 
cystitis patient [80], was used in all the experiment. The bacteria were prepared fresh for each 
experiment from frozen glycerol stock. A small aliquot of inoculum was picked up by dipping a 
sterile inoculating loop into the frozen glycerol stock and then streak out on a LB agar plate for 
overnight culture at 37℃. A single colony was picked and grown in 10ml LB broth at 37℃ 
statically. The following day, 50ul of the culture was inoculated into 50ml fresh LB broth and 
grown statically for at least 18hr to facilitate fimbriation. Bacteria were pelleted by centrifuging 
(Eppendorf Centrifuge 5810R) at 3000rpm for 15min and then re-suspended in PBS. The 
concentration of the bacteria was measured by OD600 and adjusted to 108 cfu/ml. 
Eight to fourteen-week-old female mice were induced voiding before anesthetized using 
isoflurane. 100ul of the bacteria suspension (total 107 cfu) were inoculated into the bladder by 
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transurethral catheterization. The animals were maintained under anesthesia for 7min to avoid 
immediate voiding. To label proliferating cells, EdU was dissolved in PBS to a final 
concentration of 1mg/ml, and 150ul of the EdU solution was administered through 
intraperitoneal injection (i.p.) 23hr post inoculation. Antibiotics (Sulfamethoxazole and 
Trimethoprim) were given to the mice in the drinking water starting 30hr post inoculation to 
make sure the infection was cleared. 
To assess the extent of bladder infections, urine was collected from the animals 12hr, 
24hr and 4 weeks post inoculation. 10ul urine was serially diluted and plated on LB agar plates 
for enumeration of colony formation unites. The rest of urine was used for cytospin followed by 
Hema3 staining to visualize urine sediment. 
 
2.8 Immune cell isolation and fluorescence activated cell sorting (FACS) 
Immune cells were isolated from whole blood and from the spleens. Blood samples were 
collected via cardiac puncture, then spleens were excised and mechanically disrupted before 
passing through a 100um cell strainer. Red blood cells are lysed by adding ACK lysis buffer and 
incubating at room temperature for 5min. Then immune cells were collected by spinning down at 
300xg for 5min (Eppendorf Centrifuge 5417C). Single cell suspension was obtained by re-
suspending the pellet in 300ul FACS buffer then passing through a 35um filter. Cells were sorted 
on a BD Aria II Cell sorter using 30 psi pressure and 100um nozzle aperture. Around 1000 sorted 
cells were plated into a well of 96-well plate and imaged using Zeiss Axiovert 200M. 
 
 38 
2.9 Quantification and statistical analysis 
For all graphs, data were collected from at least 3 mice per group. For each sample, 5um 
FFPE sections were collected every 50um to represent different part of the bladder. 8 sections 
were stained for quantification and at least 500 cells were counted per sample. Data were 
presented as the mean±s.d. Unpaired two-tailed Student's t-test was used to determine 










Chapter 3  
The function of PPARG in  






The urothelium is a slow cycling epithelia that lines the inner surface of the urinary tract 
from the renal pelvis to the proximal urethra, providing a crucial barrier that prevent exchange of 
ions, metabolites and other toxic substances [1], [2]. The mature urothelium is composed of three 
different cell types: basal, intermediate and umbrella cells. Umbrella cells are highly adapted to 
maintain an impermeable barrier between urine and the inside of the body. The function is 
accomplished by forming high-resistance intercellular tight junctions and a unique waterproof 
apical membrane covered in uroplakin plaques [4], [11]. Umbrella cells are specialized in 
synthesizing uroplakin proteins, assembling them into 2D crystal particles and delivering them to 
the apical surface via a unique vesicle system. Structural or functional abnormalities of the 
urothelium can compromise the barrier function and expose the underlying tissue to urine, 
resulting in harmful consequences, such as interstitial cystitis, overactive bladder, and bladder 
cancer [191].  Thus, it is important to understand the differentiation process of umbrella cells and 
the molecular mechanisms of the underpinning transcriptional network. 
PPARG is a ligand-activated transcription factor that has been implicated in regulating 
cellular differentiation in a number of epithelial cell types, including the lung and intestine [160], 
[163]. PPARG expression has also been detected in the urothelium of mice, rabbits and humans 
[167], [192]. In vitro studies in NHU cells suggested that PPARG activation promotes urothelial 
differentiation while suppressing squamous differentiation [67]. However, most of the urothelial 
cells in these studies were isolated from the ureter, which may have different characteristics from 
those in the bladder. Secondly, the function of PPARG in different urothelial cell populations in 
vivo still remains to be elucidated. Therefore, in this study, we focused on investigating the role 
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of PPARG in the urothelium in an in vivo setting using novel lines of transgenic mice, in which 
the Pparg gene is conditionally knocked out in a specific urothelial cell population. Examination 
of the urothelium from Pparg-deleted urothelium revealed that PPARG is essential for the 
formation and maintenance of superficial and intermediate cells.  
Accumulated data suggested urothelial differentiation is regulated by a transcription 
network. Transcription factors that have been proposed to be involved in the network include 
Klf5, Elf3 and Grhl3 [65], [68], [193]. However, the hierarchy of the network is largely unclear. 
Early research using PPARG agonists on cultured NHU cells showed that PPARG functioned 
through intermediary transcription factors like FOXA1 and IRF-1 [170]. Gene expression data 
from bladder cancer samples and cell lines suggested that functions of PPARG and FOXA1 were 
not in the same axis but rather in a cooperative fashion in driving the luminal subtype of bladder 
cancer, which is enriched in characteristics of umbrella cells and considered as more 
differentiated [182], [194] Research from our lab found that PPARG is significantly down 
regulated in the urothelium of retinoic acid (RA) signaling deficient mice, in which the 
urothelium becomes squamous [25]. To advance our understanding of the molecular mechanisms 
of PPARG in the urothelium and further the connections in the transcriptional network, we 
profiled the gene expression changes in PPARG-ablated urothelium. In combination with the 
analysis of PPARG binding sites, we identified Grhl3 as a direct downstream target of PPARG.  
Together, in this chapter, we reported that PPARG is essential for the formation of 
suerficial and intermediate cells. Pparg-knockout urothelium fail to form normal interemediate 
and superficial cells. PPARG also plays a critical role in superficial cell maintanence, as ablating 
PPARG from fully formed urothelium led to the loss of mature superficial cells. Furthermore, we 
discovered Grhl3 as a direct downstream target of urothelial PPARG. 
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3.2 Results 
3.2.1 PPARG expression in the urothelium 
To start understanding the function of PPARG in the urothelium, we first explored the 
expression of PPARG in the mouse bladder by immunohistochemistry. PPARG is expressed in 
the urothelium, but not in the stroma. To localize PPARG expression in the cell types in the 
urothelium, we co-stained the sections with P63 and KRT5. PPARG is co-localized in the nuclei 
of all three cell types of the urothelium, with the highest intensity in the umbrella cells (P63-, 
KRT5-), followed by intermediate cells (P63+, KRT5-) and weakest in the basal cells (P63+, 
KRT5+) (Figure 3.1).  
 
3.2.2 Knockout Pparg in the urothelium in vivo  
To explore the function of PPARG signaling in the urothelium in vivo, we decided to 
knock out the Pparg gene in the whole urothelium using the ShhCre driver, which drives 
recombination in basal and intermediate cells, resulting in deletion of Pparg gene in both cell 
types and their respective daughters. Shhtm1(EGFP/cre)Cjt/J mice [187] (referred to as ShhCre 
mice) were crossed with Pparg (tm1.1Gonz) mice (referred to as Pparg mice), which harbor a 
Pparg gene with its exon 2 floxed by two loxP sites [154]. In Cre-expressing cells, the floxed 
exon is excised and the Pparg gene is disrupted, which results in the loss of PPARG protein and 
a null allele. In ShhCre; Ppargfl/fl mice, PPARG signaling is ablated in all the urothelial cells in the 
bladder (Figure 3.2).  
 
 43 
3.2.3 Pparg is essential for the formation of superficial and intermediate cells 
Shhcre;Ppargfl/fl mutants can survive as long as their littermate controls to up to two years. 
Histological analysis of the urothelium from these mice revealed a number of abnormalities in 
the Shhcre;Ppargfl/fl mutants.  
First of all, the Pparg-deleted urothelium lacks umbrella cells. Umbrella cells sized up to 
150um in diameter usually lay the apical layer in normal bladder. However, in ShhCre;Ppargfl/fl 
urothelium, only small cuboidal-shaped cells were found on the top layer, which can be both 
mono- or bi-nucleated (Figure 3.3A,B). Immunostaining of KRT20, a specific marker for mature 
umbrella cells, showed no KRT20 signal from the ShhCre; Ppargfl/fl urothelium (Figure 3.3C, D).  
We further examined the ultrastructure of these abnormal cells using transmission 
electron microscopy. Umbrella cells in the controls showed a scallop-shaped apical surface due 
to the presence of uroplakin plaques. And their cytoplasm was filled with fusiform-shaped 
uroplakin-delivering vesicles (Figure 3.4A, C). In contrast, top cells from the urothlium of 
ShhCre; Ppargfl/fl mice have a relatively smooth apical surface. And they contain fewer and 
smaller discoidal-shaped vesicles rather than elongated fusiform vesicles (Figure 3.4B, D). But 
these abnormal cells were able to form tight junctions as seen in controls. Interestingly, gene 
expression profiling revealed a shift in tight-junction transcripts. Tight junctions that are 
enriched in normal umbrella cells such as Claudin 8 were significantly downregulated in the 
ShhCre; Ppargfl/fl urothelium, whereas those associated with interemediate and maturing umbrella 
cells like clauding 7 and claudin 3 were significantly upregulated. (Table 3.1). 
The absence of uroplakin plaques on the apical surface and mature fusiform vesicles 
implies defects in the synthesis or assembly of uroplakin proteins. Indeed, immunostaining of 
bladder sections from controls and mutants revealed that UPK1B, UPK2 and UPK3 were not 
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detectable in the mutant urothelium. Only UPK1A was detected on the apical surface, but at a 
much lower level (Figure 3.5). In accordance with this result, expression profile data from RNA 
sequencing showed a significant decrease of all the uroplakins at mRNA level (Table 3.2). 
Further analysis of bladder sections from controls and Shhcre;Ppargfl/fl mutants by 
combinational markers UPK1A, P63 and KRT5 revealed that the Pparg-ablated urothelium also 
lacks normal intermediate cells (UPK1a+ P63+). Moreover, we identified two abnormal cell 
populations in the mutant urothelium, one population is only positive for UPK1A but negative 
for P63 and K5, termed UPK1A only cells, and the other population co-expresses UPK1A and 
KRT5 but negative for P63, termed UPK1A+ KRT5+ cells. Neither population exists in normal 
urothelium. Basal cells (P63+, KRT5+) were present in the Pparg-ablated urothelium at 
comparable numbers to the controls (Figure 3.6). 
 
3.2.4 The mutant urothelium retained its barrier function but is hyperplasic 
To investigate the effects of the altered urothelial structure on barrier permeability, we 
instilled methylene blue into the bladders of Pparg-knockout mice and their littermate controls. 
The dye retained by the bladder was extracted and its concentration was measured. No 
significant difference was found in dye retention, suggesting the Pparg-ablated urothelium was 
able to differentiate or compensate to a certain degree to retain its barrier function (Figure 3.7). 
Preliminary analysis of images of the Pparg-ablated urothelium obtained from transmission 
electronic microscopy revealed that tight junctions were formed between top cells and their 
number might increase slightly (Data not shown). Consistent with these results, we did not 
observe spontaneous inflammatory response in the Pparg-depleted urothelium (Figure 3.8).  
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Next, we stained the bladder sections of the mutant urothelium with Ki67, a marker of 
proliferating cells, to determine whether the urothelium is able to maintain its quiescence. 
Normal urothelium is one of the slowest cycling epithelium, with a very low mitotic index of 
~0.01% [3], [195]. However, in the Pparg-knockout urothelium, a significant number of Ki67+ 
cells were present, suggesting the urothelium is hyperplasic (Figure 3.9). The additional tight 
junctions and cells in the urothelium may compensate for the lack of uroplakin plaques in the 
mutant top cells and contributed to the barrier function. 
 
3.2.5 The phenotype in ShhCre;Ppargfl/fl urothelium is non-progressive 
Given the hyperplasic nature of the Pparg-ablated urothelium, next question we asked 
was whether the phenotype is persistent/progressive. To answer this question, we examined the 
bladders from ShhCre; Ppargfl/fl mice at two additional time points. Animals aged to a year old did 
not show any additional phenotype (Figure 3.10A-D). The other time point we examined is post-
natal 2 weeks, by which time mature superficial cells are already formed in a wild-type 
urothelium. At the age of 2-week-old, ShhCre; Ppargfl/fl bladders already showed a similar 
phenotype to the adult samples (Figure 3.10E-H). Taken together, these results suggested that the 






3.2.6 PPARG is required for maintaining superficial cells 
 Normal superficial and intermediate cells were completely absent in ShhCre; Ppargfl/fl 
mutants. To explore the function of PPARG in those cells, we crossed Pparg mice with 
Tg(Upk2-icre/ERT2)1Ccc/J mice [188] (referred to as Up2CreERT2 mice) to specifically knockout 
Pparg in umbrella and intermediate cells after they already formed normally. 
 Up2CreERT2; Ppargfl/fl mice were induced after reaching adulthood by 3 doses of tamoxifen 
via intraperitoneal injection over a week and the bladders were harvested and examined 2 weeks 
after the last injection. Immunostaining of KRT20 on bladder sections from Up2CreERT2; Ppargfl/fl 
mice and Up2CreERT2 controls showed that in contrast to a continuous layer of KRT20+ cells 
lining the inner surface of normal bladder, KRT20+ cells were sparse in Up2CreERT2; Ppargfl/fl 
urothelium, suggesting mature umbrella cells were largely absent (Figure 3.11).  
Immnuostaining of Uroplakins showed decreased levels of UPK in the Up2CreERT2; 
Ppargfl/fl urothelium (Figure 3.12). It is worth noting that the pattern and levels of UPK 
expression in the Up2CreERT2; Ppargfl/fl mutants were similar to those in regenerating urothelium 
in response to UTI, of which intermediate cells are exposed and under the process of 
differentiating to umbrella cells. Indeed, immunostaining of Ki67 on Up2CreERT2; Ppargfl/fl 
urothelium revealed quite a few proliferating cells, suggesting the urothelium entered a 
regenerating state (Figure 3.13).  
 In term of cell types present in the Up2CreERT2; Ppargfl/fl urothelium, normal looking 
intermediate cells (UPK+, KRT5-, P63+) and basal cells (UPK-, KRT5+, p63-) were found. In 
addition, we also uncovered 2 abnormal cell populations, UPK only cells (KRT20-, UPK+, 
KRT5-, P63-) and UPK+ KRT5+ cells (UPK+, KRT5+, P63-), resembling the Upk1a only and 
Upk1a+, k5+ population in the ShhCre; Ppargfl/fl urothelium respectively (Figure 3.14A,B). 
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Quantitative analysis of each population showed the number of intermediate cells decreased 
significantly (Figure 3.14C). In combination with the newly emerged P63- cell populations, the 
results suggested that Pparg-ablated intermediate cells are able to downregulate P63 expression 
to initiate differentiation, but have defects in later stages of differentiation to generate umbrella 
cells. 
 
3.2.7 Downstream targets of PPARG in the urothelium 
 To further understand how PPARG regulates the gene network in the urothelium, we 
generated the expression profile of the ShhCre; Ppargfl/fl urothelium and their littermate controls. 
Enrichment analysis of Gene Ontology of differentially expressed genes showed that, not 
surprisingly, genes related to lipid metabolic process were significantly downregulated in the 
ShhCre; Ppargfl/fl urothelium, along with genes related to mitochondria, suggesting the Pparg-
ablated cells might have a decreased energy level. Genes related to the endoplasmic reticulum 
and apical plasma membrane were also downregulated, suggesting abnormality in the vesicle 
trafficking system (Table 3.3) Interestingly, we found genes related to immune responses were 
significantly upregulated in the ShhCre; Ppargfl/fl urothelium, but did not detect any significant 
difference of the number of immune cells in the bladders, suggesting the Pparg-ablated 
urothelium might be predisposed to additional changes when immune responses are evoked 
(Table 3.4). 
 To identify direct targets of PPARG in the urothelium, we integrated our RNAseq dateset 
with PPARG ChIPseq dataset of normal adult murine urothelium, generated in collaboration 
with Dr. Joo-Seop Park at Cincinnati Children’s Hospital (Figure 3.15). 26 genes passed through 
the filtering process (Table 3.5).  
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 One of the candidates is Grhl3. Grhl3 has been reported to be essential for the 
differentiation of umbrella cell at late stage [66]. Grhl3-/- mutants failed to develop a functional 
barrier and its phenotype was very similar to what we observed in the ShhCre; Ppargfl/fl mutants. 
Immunofluorescence staining of GRHL3 on bladder sections from ShhCre; Ppargfl/fl mutants and 
Upk2CreERT; Ppargfl/fl mutant showed decreased expression level of GRHL3 in Pparg-ablated 





PPARG is known for its functions in cell differentiation in several epithelia. In vitro 
studies in NHU cells showed PPARG is involved in differentiating urothelial cells. In this 
chapter, we explored the function of PPARG in the urothelium in vivo. Using a conditional 
targeting strategy to delete the Pparg gene in specific urothelial cell populations in mice, we 
found PPARG is necessary for the formation and maintenance of the superficial and intermediate 
cells. 
PPARG ablation from all the urothelial cells during development using ShhCre;Ppargfl/fl 
line resulted in a urothelium lacking of normal umbrella and intermediate cells which were 
replaced by two abnormal cell populations, UPK1A+ only cells and UPK1A+, KRT5+ cells, 
which do not exist in wild-type urothelium. Similar abnormality was observed in 
Upk2CreERT2;Ppargfl/fl line where the Pparg gene was knocked out in superficial and intermediate 
cells after they were already formed. Deleting the Pparg gene in Upk2-expressing cells before 
and after the formation of umbrella/intermediate cells ended up with similar abnormal top cells, 
implying that those cells might be at an intermediary stage between intermediate cells and 
umbrella cells. The differentiation of umbrella cells is a complex process and numerous changes 
have been observed. However, little is known in terms of the sequences of those changes due to 
the quiescent nature of urothelium during homeostasis and the rapid but asynchronized 
regeneration after injury. Further characterize these two abnormal populations might shed some 
lights on this dark alley of differentiation and help to assemble the differentiation process in 
order. 
Current understanding of the intermediate cell population is very limited, due to both a 
long-time misunderstanding that it is just a transit population between stem cells and terminal 
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differentiated cells, as well as technical limitation in which no specific intermediate cell marker 
has been identified yet. As a result, it remains largely unknown how intermediate cells balance 
self-renewal and differentiation. Further characterizing the changes in the Upk2CreERT2;Ppargfl/fl 
line from a temporal aspect might reveal the signals that are critical for this balance.  
Previous work from our lab demonstrated that umbrella/intermediate cells and basal cells 
are from distinct lineages. The UPK1A+, KRT5+ population is particularly interesting because a 
similar population, KRT5+, P63-, UPK+/- cells, is frequently observed in bladder cancer or other 
pathological conditions and considered as decedents of basal cells. The UPK1A+, KRT5+ 
population emerged after targeted deletion of Pparg in Upk2-expressing cells raise the possibility 
that cells from umbrella/intermediate cell lineage might be able to express markers for basal cell 
lineage in certain conditions.  
We were interested in determining the functional consequences of the observed 
abnormality. However, we observed no evidence of bladder leakiness or inherited inflammation.  
The phenotype is persistent, but not progressive, at least up to a year. It will be interesting to 
understand better how this abnormal urothelium compensate to retain its barrier function. 
Preliminary results from transmission electronic microscopy indicated that the Pparg-depleted 
urothelium might has more tight junctions between adjacent cells. It will be interested to know 
whether they form other forms of junctions to further strengthen the barrier function. 
Molecular characterization of the urothelium from the ShhCre;Ppargfl/fl line using 
combined RNAseq and ChIPseq identified 26 direct targets of PPARG. We verified that the 
expression of GRHL3, which has been reported as an essential regulator of urothelium 
differentiation, is regulated by PPARG in the urothelium. Other candidates including Reg3g and 

































Gene symbol Fold p-value 
Cldn3 369.00 2.21E-137 
Cldn4 1.02 8.17E-01 
Cldn7 2.19 2.01E-27 
Cldn8 0.15 1.29E-87 
Cldn23 1.89 9.11E-11 
Cldn25 1.15 3.24E-01 
Ocln 1.96 5.88E-32 
Tjp1 1.29 7.30E-05 
Cdh1 2.26 2.90E-36 
Table 3.1 Expression of adhesion genes in ShhCre;Ppargfl/fl  urothelium 
 
Table 3.2 
Gene symbol Fold p-value 
Upk1a 0.40 2.13E-57 
Upk1b 0.30 1.23E-18 
Upk2 0.47 2.79E-11 
Upk3a 0.17 2.34E-47 
Upk3b 0.09 3.08E-11 





Table 3.3 Enrichment analysis of gene ontology (GO) of genes down-regulated in 
ShhCre;Ppargfl/fl  urothelium 
ID Name Q-value Hit count in 
query list 
Hit count in 
genome 
GO: Molecular Function 
   
GO:0048037 cofactor binding 2.61E-09 32 277 
GO:0016491 oxidoreductase activity 1.01E-08 54 749 
GO:0050662 coenzyme binding 5.71E-07 23 192 
GO:0003857 3-hydroxyacyl-CoA dehydrogenase 
activity 
4.19E-04 5 9 
GO:0000062 fatty-acyl-CoA binding 4.19E-04 8 33 
GO:0051287 NAD binding 4.25E-04 10 57 
GO:0016616 oxidoreductase activity, acting on 
the CH-OH group of donors, NAD 
or NADP as acceptor 
5.77E-04 14 120 
GO:0042802 identical protein binding 2.11E-03 62 1359 
GO:0004303 estradiol 17-beta-dehydrogenase 
activity 
2.83E-03 5 14 
GO:0016614 oxidoreductase activity, acting on 
CH-OH group of donors 
3.86E-03 14 146 
GO: Biological Process 
   
GO:0006629 lipid metabolic process 6.22E-18 101 1377 
GO:0043436 oxoacid metabolic process 6.22E-18 89 1114 
GO:0006082 organic acid metabolic process 9.59E-18 89 1131 
GO:0019752 carboxylic acid metabolic process 9.59E-18 83 1003 
GO:0044255 cellular lipid metabolic process 1.11E-15 82 1064 
GO:0006631 fatty acid metabolic process 2.22E-14 45 379 
GO:0032787 monocarboxylic acid metabolic 
process 
2.51E-14 58 617 
GO:0055114 oxidation-reduction process 2.73E-14 76 996 
GO:0008610 lipid biosynthetic process 1.71E-13 59 667 
GO:0044282 small molecule catabolic process 2.05E-11 40 370 
GO: Cellular Component 
   
GO:0005783 endoplasmic reticulum 1.06E-08 91 1706 
GO:0005789 endoplasmic reticulum membrane 2.38E-07 60 994 
GO:0042175 nuclear outer membrane-
endoplasmic reticulum membrane 
network 
3.52E-07 60 1015 
GO:0042579 microbody 4.95E-07 19 142 
GO:0005777 peroxisome 4.95E-07 19 142 
GO:0044432 endoplasmic reticulum part 5.26E-07 65 1177 
GO:0005739 mitochondrion 5.23E-06 83 1769 
GO:0016324 apical plasma membrane 1.34E-05 27 335 
GO:0045177 apical part of cell 5.06E-05 30 428 
GO:0005759 mitochondrial matrix 2.89E-04 28 425 
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Table 3.4 Enrichment analysis of gene ontology (GO) of genes up-regulated in 
ShhCre;Ppargfl/fl  urothelium 




GO: Molecular Function 
   
GO:0008236 serine-type peptidase activity 1.46E-02 18 242 
GO:0008329 signaling pattern recognition receptor 
activity 
1.46E-02 5 17 
GO:0038187 pattern recognition receptor activity 1.46E-02 5 17 
GO:0017171 serine hydrolase activity 1.46E-02 18 245 
GO:0019834 phospholipase A2 inhibitor activity 1.46E-02 3 4 
GO:0005102 receptor binding 1.46E-02 65 1601 
GO:0005154 epidermal growth factor receptor 
binding 
2.14E-02 6 33 
GO:0004668 protein-arginine deiminase activity 2.14E-02 3 5 
GO:0001875 lipopolysaccharide receptor activity 2.14E-02 3 5 
GO:0044548 S100 protein binding 2.71E-02 4 13 
GO: Biological Process 
   
GO:0006952 defense response 9.71E-18 109 1651 
GO:0045087 innate immune response 9.71E-18 74 846 
GO:0006955 immune response 3.93E-17 104 1572 
GO:0050776 regulation of immune response 9.60E-15 71 899 
GO:0045088 regulation of innate immune response 1.79E-14 44 375 
GO:0002682 regulation of immune system process 9.28E-14 94 1506 
GO:0031347 regulation of defense response 4.87E-13 64 820 
GO:0080134 regulation of response to stress 4.87E-13 95 1579 
GO:0002684 positive regulation of immune system 
process 
1.24E-11 68 976 
GO:0040012 regulation of locomotion 1.63E-11 63 866 
GO: Cellular Component 
   
GO:0005773 vacuole 4.14E-06 63 1223 
GO:0000323 lytic vacuole 4.14E-06 37 539 
GO:0005764 lysosome 4.14E-06 37 539 
GO:0005615 extracellular space 6.04E-06 70 1449 
GO:0031410 cytoplasmic vesicle 8.06E-06 66 1355 
GO:0097708 intracellular vesicle 8.06E-06 66 1357 
GO:0030054 cell junction 1.12E-05 60 1200 
GO:0016323 basolateral plasma membrane 1.28E-05 22 244 
GO:0045177 apical part of cell 1.95E-05 30 428 
GO:0031226 intrinsic component of plasma 
membrane 
1.95E-05 76 1714 
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Table 3.5 Potential direct targets of urothelial PPARG 
Gene Name peak score Fold p-value 
4931406C07Rik 63.32 0.23 1.60E-136 
Fbp2 126.79 0.30 1.28E-11 
Hyal2 59.99 0.31 3.91E-48 
Tob1 87.96 0.31 1.70E-34 
Acox1 74.97 0.38 6.01E-35 
Me1 234.93 0.39 4.84E-09 
Stt3b 77.01 0.42 4.64E-27 
Lpcat3 301.86 0.44 4.60E-37 
Cdc42ep3 74.88 0.44 2.31E-18 
Bcar3 70.64 0.45 4.28E-19 
Aldh9a1 73.09 0.45 2.33E-51 
Upk2 59.16 0.47 2.79E-11 
Nadk 106.06 0.48 1.24E-32 
Agpat1 51.82 0.51 1.07E-22 
Acads 121.73 0.52 2.32E-23 
Hspe1 651.73 0.54 5.85E-04 
Rps19 83.83 0.55 2.09E-15 
Grhl3 74.74 0.58 1.00E-06 
Ech1 119.26 0.58 2.34E-18 
Etfb 62.55 0.61 1.20E-23 
Ehmt2 105.56 1.65 2.82E-15 
Zfand5 61.46 1.83 2.42E-07 
Cldn23 52.9 1.89 9.11E-11 
Eps8l1 66.19 1.90 6.44E-21 
Cbr2 87.43 5.56 1.45E-43 











The function of PPARG in response to UTI   
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4.1 Introduction 
Urinary tract infections (UTIs) are among the most common infectious diseases in 
human, resulting in nearly 8 million patient visits every year in the U.S. and imposing a 
substantial burden on medical cost, with an estimated annual cost exceeding $1 billion [196]. 
Uropathogenic Escherichia coli (UPEC), the major causative agent of UTI, accounts for more 
than 80% of the incidences. UPEC infection of the bladder elicits a rapid host response 
characterized by urothelial cell exfoliation concomitant with acute inflammation. Urothelium 
possesses remarkable regenerative ability and could restore its barrier function within days [87] 
(Figure 4.1).   
The robust but transient innate immune defenses and regenerative responses are tightly 
controlled and carefully orchestrated, as both insufficient and excess responses will lead to 
detrimental consequences. As one could imagine, inadequate urothelial regeneration generates a 
compromised barrier which exposes underlying tissue to toxic substances or other pathogens in 
the urine whereas unrestrained proliferation sets the stage for tumor development. Studies in 
mouse strains with defects in innate immune responses have demonstrated that failure to recruit 
immune cells into the bladder leads to decreased ability of bacteria clearance and increased 
susceptibility to recurrent infections, whereas excessive inflammation results in bladder tissue 
damage and predisposes the host to chronic diseases such as chronic cystitis [95][91]. Mounting 
evidence suggests the urothelial cells play a key role in initiating and modulating the immune 
responses. Understanding how the urothelium regulates the level and the timing of reactions to 
UTI will shed lights on designing strategies for tissue regeneration and designing therapeutic 
approaches to UTI and other urinary diseases.  
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PPARG belongs to the ligand-dependent nuclear hormone receptor superfamily and 
regulates diverse biological processes including lipid and glucose metabolism, inflammation, and 
cellular proliferation and differentiation [197]. As we discussed in the previous chapter, PPARG 
could promote cellular differentiation in a number of epithelium, including the urothelium 
[163][160]. Multiple studies have also demonstrated that PPARG plays an anti-inflammatory 
role in immune responses by interfering with pro-inflammatory signaling such as NF-kB [122]. 
Therefore, defects in PPARG might lead to persistent inflammation even after the pathogens are 
cleared. Chronic inflammation is a risk factor to cancer in multiple organs [198]. Indeed, recent 
discoveries in the claudin-low subtype of bladder cancer, which has decreased level of PPARG, 
supported this theory by showing elevated level of cytokines and chemokines and increased 
immune cell infiltration in those tumors [186]. The pleiotropic functions of PPARG make it a 
promising link between urothelial regeneration and inflammation. In the previous chapter, we 
reported that the bladders from ShhCre; Ppargfl/fl mutants did not spontaneously elicit an 
inflammatory response, but rather exhibited elevated expression levels of immune related genes. 
In this chapter, we explored the function of PPARG after challenging the ShhCre; Ppargfl/fl  
mutants with UPEC-mediated infections. Here, we reported that Pparg ablation leads to 
squamous metaplasia as well as chronic inflammation in the bladder, and may predispose the 









4.2.1  Pparg ablation in basal cell population resulted in an increase of KRT14+ basal cells 
Basal cell population of the urothelium has been reported as heterogeneous. KRT14+ 
basal cells have been considered as a less differentiated population that serves as progenitors in 
the urothelium and play a pivotal role in regeneration and tumorigenesis of bladder cancer [33]. 
Elevated KRT14 expression is also a feature observed in squamous differentiation [67], [199]. 
Expression profiling of bladder cancers showed that decreased PPARG expression was 
correlated with increased KRT14 expression in the basal subtype of bladder cancer. Further 
probing the basal population in the urothlium from ShhCre; Ppargfl/flmutants revealed an increased  
number of KRT14+ basal cells (Figure 4.2).  
To explore whether this is an effect of PPARG on basal cells directly, Pparg gene was 
specifically knocked out in basal cells using a Krt5CreERT2 driver. Tg(KRT5–cre/ERT2)2Ipc/JeldJ 
mice (referred to as Krt5CreERT2 mice) were crossed with Pparg mice to generate Krt5CreERT2; 
Ppargfl/fl mice. Co-staining of KRT14 and PPARG on bladder sections of Krt5CreERT2; Ppargfl/fl 
mice showed the majority of Pparg-ablated basal cells were KRT14+ (Figure 3.19A, B). On the 
other hand, no difference has been found in basal cells in the urothelium of Upk2CreERT2; Ppargfl/fl 
mice (Figure 4.3). Taken together, our results suggested that PPARG has a direct effect in basal 
cells. Loss of PPARG in the basal cell population resulted in an increase of the number of 
KRT14+ basal cells.  
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4.2.2 Urinary tract infection could be established in ShhCre;Ppargfl/fl mutants  
 We hypothesized that the increased number of KRT14+ basal cells may predispose the 
urothelium to squamous differentiation in response to external stimulus. To explore this 
hypothesis, we challenged the ShhCre;Ppargfl/fl urothelium with UPEC-mediated injury. 
Given the defects in the ShhCre;Ppargfl/fl urothelium, first we tested whether it could be 
infected by UPEC. UTI89, a UPEC strain that originally isolated from a human patient with 
acute cystitis [200], was instilled into mutant or littermate control bladders via transurethral 
inoculation. Urine was collected at different time points, serially diluted and plated to measure 
bacterial burden. CFU measurement at 12 hours and 24 hours post infection showed no 
difference between mutants and controls (Figure 4.4A). Urine sediment from both controls and 
mutants contains bacteria, shedded urothelial cells and neutrophils (Figure 4.4B,C). Taken 
together, the results demonstrated that ShhCre;Ppargfl/fl mutants could be infected by UPEC. 
Next, we compared the kinetics of bacteria clearance by immunostaining bladder sections 
harvested at different time points post UPEC infection. In the samples harvested at 12 hours post 
infection, E.coli were present both inside and on the surface of urothelial cells in ShhCre;Ppargfl/fl 
mutants and littermate controls.  However, no identifiable IBC was found in mutant samples, 
which could be at least partially attributed to the smaller cell size and the immature vesicle 
trafficking system in ShhCre;Ppargfl/fl urothelium (Figure 4.5A, B). Bacteria were sparse by 24 
hours after UTI, suggesting the majority of bacteria have been cleared by this time (Figure 4.5C, 
D). Animals were given antibiotics in drinking water starting at 30 hours post infection to help 
clear up the infection. We confirmed bacteria clearance again 4 week after UTI, no bacteria were 
found by urine cultures and by immunostaining bladder sections against E.coli (Figure 4.2A, 
4.3E, F).  
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4.2.3 Early inflammatory and regenerative responses in ShhCre;Ppargfl/fl mutants after UTI 
  To explore whether ShhCre;Ppargfl/fl mutants are able to initiate inflammatory and 
regenerative responses to UPEC-mediated injury, we further analyzed bladder samples harvested 
24 hours post infection.  
Rapid NF-kB activation has been reported in the urothelium after UTI and plays a central 
role in mediating inflammation. Immunostaining of NF-kB subunit p65 on bladder sections from 
both ShhCre;Ppargfl/fl mutants and their littermate controls showed robust nuclei-localized signal 
in the urothelium, suggesting Pparg-ablated urothelium are able to trigger inflammatory 
response (Figure 4.6A,B).  
In normal urothelium, proliferation of urothelial cells peaks around 24 hours post 
infection and has been confirmed in our littermate control sample by Ki67 staining (Figure 
4.6C). The same marker also revealed plenty of proliferating cells in the Pparg-ablated 
urothelium (Figure 4.6D).  
Taken together, our results suggested that ShhCre;Ppargfl/fl mutants were able to initiate 
inflammatory and proliferative responses after UTI. 
 
4.2.4 ShhCre;Ppargfl/fl mutant failed to repopulate its UPK1A-expressing cells after UTI  
To further investigate which population(s) is able to proliferate, we administrated EdU, a 
nucleoside analog which can incorporate into DNA during active DNA synthesis, at 23 hours 
post infection, one hour before sacrifice the animals to label newly formed cells. 
Interestingly, co-staining EdU with KRT5 and UPK1A revealed that the proliferation 
ability is confined to the basal cell compartment, whereas neither of the two UPK1A-expressing 
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populations in the ShhCre;Ppargfl/fl urothelium, UPK1A+ only and UPK1A+, KRT5+ cells, have 
regenerative ability, as no cell in the mutant urothelium was EdU and UPK1A double positive 
(Figure 4.7B).  
Analysis of samples from a later time point (4 weeks post infection) showed that there 
were very few if any UPK expressing cells (Figure 4.7D), suggesting that not only UPK-
expressing cells do not have self-renewal capability, but the basal cells in the ShhCre;Ppargfl/fl 
mutant also were unable to give rise to UPK+ cells.  
Instead, the KRT5+ cell population expanded throughout the urothelium. One thing 
worth noting is that some of the KRT5+ cells are P63-, which do not exist in normal urothelium 
but have been observed in bladder cancers. 
 
4.2.5 Pparg-ablation in the urothelium leads to squamous metaplasia post infection 
KRT14+ basal cells have been reported to play a pivotal role in regeneration [33] and the 
urothelium of the ShhCre;Ppargfl/fl mutants exhibited an increased number of KRT14+ cells under 
homeostasis (Figure 4.8A,B). To assess their response to UTI, we stained KRT14 on bladder 
sections 24 hours post infection. At this time point, more basal cells expressed KRT14+ in wild-
type urothelium, but they were exclusively located in the basal-most layer (Figure 4.8C). In 
contrast, clonal expansion of KRT14+ cells were found in ShhCre;Ppargfl/fl urothelium, with 
KRT14 expression all the way to the top layer (Figure 4.7D). KRT14 expansion has been 
reported in the urothelium that undergoes squamous differentiation, such as in vitamin-A 
deficient mice [33], [201]. Further analysis of samples harvested 72 hours post infection revealed 
multiple squamous lesion with KRT14+ cells throughout all layers (Figure 4.8F). 
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 To determine whether the squamous lesion is progressive, we examined the bladders 
from ShhCre;Ppargfl/fl mutants and littermate controls 4 weeks post infection, by which time wild-
type urothelium is fully repaired. Histological analysis of the bladder sections from 
ShhCre;Ppargfl/fl mice revealed significant abnormalities in the urothelium. In littermate controls, 
the urothelium was already restored the relatively thin, well-organized structure composed by 3-
4 layers of cells (Figure 4.9A). In contrast, the mutant urothelium is in a disarray, with pockets of 
immune cells mingling in the urothelium or bursting open to the lumen (Figure 4.9B). The 
urothelium of ShhCre;Ppargfl/fl mutants was also thicker than controls, with an increase in cell 
layers to 4-5 layers. A closer look at the urothelial cells in the mutants showed that they were 
smaller, round in shape and organized in a more compact pattern comparing to controls, all of 
which are features of squamous cells.  
Immunostaining of KRT14 and KRT5 revealed that the wild-type urothlium only had a 
few KRT14+ cells, and all of which were exclusively attach to the basement membrane. In 
contrast, the urothelium of ShhCre;Ppargfl/fl mutants exhibit lesions that were composed of 
KRT14+ KRT5+ cells throughout all layers. 
To further confirm the ShhCre;Ppargfl/fl urothelium underwent squamous differentiation, 
we stained the sections mentioned above with additional squamous markers. KRT13 is not 
detected in normal urothelium in the bladder, but expressed in the differentiated cells of non-
cornified stratified squamous epithelium, such as the esophagus, ureters and urethral [202]. 
KRT10 is not expressed in normal urothelium either, but it is a marker for differentiated 
keratinocytes in the suprabasal layer of the skin [203]. Pparg-ablated urothelium developed focal 
lesions after UTI with dramatic expansion of KRT13 and KRT10 expressing cells throughout all 
layers (Figure 4.9E-H). It is worth noting that the expression of these three squamous markers 
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(KRT14, KRT13, KRT10) did not completely overlap, suggesting those cells may have different 
degrees of squamous differentiation. Altogether, these results demonstrated that PPARG 
expression is required for urothelial regeneration and loss of PPARG results in squamous 
metaplasia in the bladder. 
 
4.2.6 Knockout urothelial Pparg led to persistent inflammation after UTI 
Bladders from ShhCre;Ppargfl/fl mutants also displayed dramatic changes in their stromal 
compartment 4 weeks post infection. Instead of a thin layer of stroma with sparse fibroblasts 
observed in the wild-type bladders, the stroma in ShhCre;Ppargfl/fl mutants exhibited remarkable 
edema and granulation tissue with excessive immune cell infiltration right beneath the basement 
membrane, indicating persistent inflammation (Figure 4.10). 
To identify which immune cell population participated in the prolonged inflammatory 
responses, we stained the bladder sections from ShhCre;Ppargfl/fl mice and their littermate controls 
4 weeks post infection with a panel of immune cell markers. CD45 is a common antigen of 
leukocytes, including neutrophils and monocytes. F4-80 is a marker specifically expressed by 
macrophages. CD3 is a pan marker for T cells whereas CD19 is a pan B cell marker. Very few 
immune cells were present in the control tissues (Figure 4.11A, C, E). In contrast, there were 
plenty of neutrophils, macrophages and T cells in the stroma and the urothelium in the 
ShhCre;Ppargfl/fl mutants (Figure 4.11B, D, F). Furthermore, we also found that fibroblasts in the 
stroma of ShhCre;Ppargfl/fl mutants remained activated by α-SMA staining (Figure 4.11G,H). 
Activated fibroblasts play an important role in wound repair and can secret an array of pro-
inflammatory factors. No B cell has been detected in either bladders of ShhCre;Ppargfl/fl mutants 
or their littermate controls (Figure 4.12).  
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Taken all together, the results demonstrated that ShhCre;Ppargfl/fl mice suffered from 
chronic inflammation after UTI. 
 To rule out that ShhCre;Ppargfl/fl mutants have defects in immune cells and lead to the 
inflammation phenotype directly, we crossed ShhCre;Ppargfl/fl  mice with Gt(ROSA)26Sor 
tm4(ACTBtdTomato,-EGFP)Luo/J mice [190] (referred to as mTmG mice), which harbor a two-
color fluorescent reporter allele in R26R locus. Prior to Cre-mediated recombination, all cells 
express membrane-bound tdTomato (mT). Upon Cre-mediated recombination, mT cassette is 
deleted, allowing the expression of the membrane-bound EGFP (mG) cassette located just 
downstream. Therefore, all Shh-expressing Pparg-depleted cells and their offspring are GFP+. 
To examine the immune cells, we harvest cells from both the periphery blood and the spleen, 
dispersed them into single cells suspension, and analyzed by FACS and microscopy. No GFP+ 
immune cell has been found in either assay, confirming that the phenotype was caused by the 
defect in the urothelium (Figure 4.13-14).  
 Several pro-inflammatory pathways play a central role in regulating the production of 
inflammatory mediators and the recruitment of immune cells. The timing of their termination is 
critical for proper urotheliual regeneration. Abnormal activation of NF-kB and IL6/STAT3 
pathways stood out in the genome-wide expression profiling of ShhCre;Ppargfl/fl urothelium 4 
weeks post infection.  
The NF-kB protein complex usually resides in the cytoplasm and is bound by IkB 
proteins to remain in an inactive state. Upon activation, IkB proteins are phosphorylated and 
targeted for degradation, which release NF-kB protein complex to translocate to the nucleus and 
initiate the expression of targets, including a panel of pro-inflammatory proteins [204]. 
Numerous studies have shown that PPARG participates in sequestering NF-kB signaling via 
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diverse mechanisms [129].  In the urothelium, It has been shown that the NF-kB pathway is 
activated transiently in response to UTI [88]. Immunostaining of NF-kB subunit p65 on bladder 
sections from ShhCre;Ppargfl/fl mice and their littermate controls 4 weeks post infection showed 
diffused cytoplasmic signal in the normal urothelium, whereas intense nuclei-localized signal in 
the Pparg-ablated urothelium, suggesting the mutants failed to terminate NF-kB activation 
(Figure 4.15A, B). Similarly, immunostaining of pSTAT3, the activated form of STAT3, showed 
strong STAT3 activity in the mutant urothelium and stroma, but not in the littermate controls 
(Figure 4.15C, D).  
 
4.2.7 Urothelial cells in the ShhCre;Ppargfl/fl mutants exhibit invasive behavior after UTI 
 Chronic inflammation can lead to additional changes in epithelial cells, such as the 
epithelial–mesenchymal transition (EMT), which in turn can result in an elevated risk of tumor 
formation and invasion [198].  
To explore whether urothelial cells in the ShhCre;Ppargfl/fl mutants undergo EMT, we 
stained the bladder sections from ShhCre;Ppargfl/fl mice and their littermate controls 4 weeks post 
infection for SLUG+SNAIL, a stromal cell marker that is elevated in cells undergo EMT [205]. 
No signal was detected in the urothelium in the controls, whereas a great number of 
SLUG+SNAIL positive urothelial cells were present in ShhCre;Ppargfl/fl mutants, suggesting they 
might be adapting to a more mesenchymal phenotype (Figure 4.16A, B).  
For invading cells, the first obstacle they encounter is the basement membrane, which is a 
thin, fibrous layer of extracellular matrix that separates the epithelium from the stroma. Given 
the active influx of immune cells in the ShhCre;Ppargfl/fl urothelium, it is not surprising to find the 
basement membrane was disrupted in the mutants. Indeed, immunostaining of laminin, a major 
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component of the basement membrane [206], showed that instead of a continuous thin lining 
between urothelium and stroma, the basement membrane in ShhCre;Ppargfl/fl was greatly 
fragmented, which could facilitate the cell invasion (Figure 4.16C, D).  
In breast cancer, it has been reported that KRT14 expressing cells are the invasive leader 
cells and critical for tumor dissemination [207]. Detailed examination of KRT14 staining on 
ShhCre;Ppargfl/fl mutants revealed KRT14+ cells formed protrusions into the stroma (Figure 
4.16F).  
To explore whether this phenotype is progressive, we collected samples 6 weeks post 
infection. Lesions in these samples exhibited high levels of KRT5, KRT10, KRT14, proliferating 
cells along the most-basal layer, fragmented basement membrane and KRT14+ protrusions, all of 
which resemble basal subtype of bladder cancers (Figure 4.17). However, analysis of bladders 
from ShhCre;Ppargfl/fl  mutants 6 months post infection did not uncover any full-bloom tumor, 





The basal cell population has been known for its heterogeneity for a long time. Further 
probing into the basal compartment of the ShhCre;Ppargfl/fl urothelium revealed an increased 
number of KRT14+ basal cells, which are considered to play pivotal roles in squamous 
differentiation and tumorigenesis [33]. We further confirmed that PPARG functions in basal 
cells in a cell-autonomous manner by deleting Pparg specifically in basal cells. It is worth noting 
that not all Pparg-ablated basal cells in our study express KRT14, suggesting the heterogeneity 
in the basal cell population is also regulated by other signaling pathways. 
We suspected that the increased number of K14+ basal cells combined with elevated 
expression of immune related genes may predispose the urothelium to pathological progression 
after injury. To assess the regenerative response of the Pparg-depleted urothelium, we 
challenged the Pparg-ablated urothelium with UPEC-mediated infection. Immunofluorescence 
staining of a panel of squamous markers demonstrated that lesions of squamous metaplasia 
emerged in the Pparg-depleted urothelium post infection. It will be interesting to determine 
whether the lesions are originated from the expansion of a preexistent KRT14+ basal cell 
population or from re-directing KRT14- basal cells to squamous differentiation and turn on 
KRT14 expression.  
PPARG is appreciated as a modulator of inflammatory responses in multiple diseases 
[124], [161], [164]. But the particular role of PPARG in epithelial cells is less clear. Results in 
this chapter demonstrate the important contribution of urothelial PPARG in regulating 
inflammation after UTI. Bladders with Pparg-ablated urothelium exhibited significant edema 
and granulation tissue. Massive amount of immune cells were present in the mutant bladder long 
after the infection was cleared and the barrier was restored in wild-type urothlium. These data 
 84 
indicated that urothelial PPARG is critical in terminating the inflammatory responses triggered 
by UPEC infection, and that ablation of urothelial PPARG led to prolonged inflammation for 
months. Our results also indicated that the persistent activation of NF-kB and STAT3 signaling 
pathways contributed to the chronic inflammation in the Pparg-delated urothelium. But further 
studies are needed to determine whether PPARG regulates their functions directly, and if yes, 
through which mechanism.  
However, the inflammation in the ShhCre;Ppargfl/fl mutant in response to UTI could 
eventually be resolved, as shown in animals recovered from UTI for a year (Figure 4.18), 
implying that other anti-inflammatory signals can compensate for the loss of PPARG in the 
urothelium. It will be interesting to challenge the ShhCre;Ppargfl/fl  mice with multiple rounds of 
UTI to determine whether they will develop fibrosis or interstitial cystitis, neither of which 
currently has a good animal model to study it in. 
Mounting evidence suggests that chronic inflammation increases the risk of cancer [198]. 
Recent whole genome expression analysis of samples from muscle invasive bladder cancer 
(MIBC) patients showed that basal subtype of MIBC exhibits features of squamous 
differentiation and significant immune cell infiltration [183], [185], [208], characters also 
observed in the Pparg-ablated urothelium after UTI. Basal subtype of MIBC is considered to be 
less differentiated and more aggressive with poor diagnosis. Analysis of the Pparg-depleted 
urothelium 4 weeks post infection unveiled that the urothelial cells exhibited invasive behaviors. 
Moreover, PPARG expression in the basal subtype is significantly downregulated, though its 
functional importance remains unclear. It is our interest to determine if there is a causal 
relationship between these two pathological conditions. Results from animals recovered from a 
single UTI for a year showed, however, the lesions did not spontaneously progress to tumor, 
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indicating that PPARG deficiency alone might not be enough for tumorigenesis in the bladder. 
Mining the whole-genome sequencing data of MIBC patients will be of great help in identifying 







































Table 4.1 Enrichment analysis of gene ontology (GO) of genes down-regulated in 
ShhCre;Ppargfl/fl  urothelium 




GO: Molecular Function 
   
GO:0005154 epidermal growth factor receptor 
binding 
1.02E-03 8 33 
GO:0004175 endopeptidase activity 8.00E-03 27 457 
GO:0008236 serine-type peptidase activity 8.00E-03 18 242 
GO:0017171 serine hydrolase activity 8.00E-03 18 245 
GO:0005102 receptor binding 8.00E-03 64 1601 
GO:0019834 phospholipase A2 inhibitor activity 1.09E-02 3 4 
GO:0004252 serine-type endopeptidase activity 1.13E-02 16 215 
GO:0005125 cytokine activity 1.44E-02 16 222 
GO:0004668 protein-arginine deiminase activity 1.69E-02 3 5 
GO:0070011 peptidase activity, acting on L-amino 
acid peptides 
1.69E-02 32 661 
GO: Biological Process 
   
GO:0006952 defense response 3.10E-19 109 1651 
GO:0006955 immune response 2.22E-16 100 1572 
GO:0045087 innate immune response 6.25E-16 69 846 
GO:0002682 regulation of immune system process 1.98E-13 91 1506 
GO:0031347 regulation of defense response 4.08E-12 61 820 
GO:0002684 positive regulation of immune system 
process 
6.61E-12 67 976 
GO:0050776 regulation of immune response 1.48E-11 63 899 
GO:0080134 regulation of response to stress 1.48E-11 89 1579 
GO:0031349 positive regulation of defense response 2.87E-11 41 427 
GO:0051707 response to other organism 2.02E-10 64 986 
GO: Cellular Component 
   
GO:0005773 vacuole 3.73E-03 49 1223 
GO:0016328 lateral plasma membrane 4.02E-03 7 53 
GO:0005604 basement membrane 4.29E-03 10 109 
GO:0031012 extracellular matrix 6.37E-03 23 444 
GO:0016324 apical plasma membrane 6.52E-03 19 335 
GO:0030863 cortical cytoskeleton 7.27E-03 9 97 
GO:0098552 side of membrane 7.50E-03 25 510 
GO:0005602 complement component C1 complex 7.66E-03 2 2 
GO:0035692 macrophage migration inhibitory factor 
receptor complex 
7.66E-03 2 2 
GO:0033257 Bcl3/NF-kappaB2 complex 7.66E-03 2 2 
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Table 4.2 Enrichment analysis of gene ontology (GO) of genes down-regulated in 
ShhCre;Ppargfl/fl  urothelium 




GO: Molecular Function 
   
GO:0048037 cofactor binding 8.92E-15 38 277 
GO:0016491 oxidoreductase activity 4.07E-13 60 749 
GO:0050662 coenzyme binding 1.54E-11 28 192 
GO:0042802 identical protein binding 3.96E-07 71 1359 
GO:0000062 fatty-acyl-CoA binding 1.09E-06 10 33 
GO:0016616 oxidoreductase activity, acting on the CH-OH 
group of donors, NAD or NADP as acceptor 
9.20E-06 16 120 
GO:0042803 protein homodimerization activity 1.62E-05 47 826 
GO:0016614 oxidoreductase activity, acting on CH-OH 
group of donors 
1.99E-05 17 146 
GO:0016627 oxidoreductase activity, acting on the CH-CH 
group of donors 
5.46E-05 14 107 
GO:0003857 3-hydroxyacyl-CoA dehydrogenase activity 1.35E-04 5 9 
GO: Biological Process 
   
GO:0006629 lipid metabolic process 1.96E-30 118 1377 
GO:0043436 oxoacid metabolic process 3.46E-26 99 1114 
GO:0006082 organic acid metabolic process 7.80E-26 99 1131 
GO:0008610 lipid biosynthetic process 1.37E-25 75 667 
GO:0044255 cellular lipid metabolic process 1.70E-25 95 1064 
GO:0019752 carboxylic acid metabolic process 3.50E-24 90 1003 
GO:0006631 fatty acid metabolic process 5.62E-22 53 379 
GO:0032787 monocarboxylic acid metabolic process 3.23E-21 66 617 
GO:0044283 small molecule biosynthetic process 3.90E-20 62 572 
GO:0055114 oxidation-reduction process 6.83E-19 81 996 
GO: Cellular Component 
   
GO:0005783 endoplasmic reticulum 5.43E-14 100 1706 
GO:0005789 endoplasmic reticulum membrane 3.24E-13 70 994 
GO:0042175 nuclear outer membrane-endoplasmic 
reticulum membrane network 
6.22E-13 70 1015 
GO:0044432 endoplasmic reticulum part 7.58E-13 76 1177 
GO:0005777 peroxisome 7.58E-13 25 142 
GO:0042579 microbody 7.58E-13 25 142 
GO:0044438 microbody part 8.90E-08 16 96 
GO:0044439 peroxisomal part 8.90E-08 16 96 
GO:0005782 peroxisomal matrix 9.79E-06 10 48 










Our findings demonstrate that PPARG plays distinct roles in different types of urothelial 
cell. PPARG ablation in the urothelium resulted in the absence of umbrella and intermediate 
cells, the emergence of two abnormal cell populations, and caused an increased number of 
KRT14+ basal cells. While previous studies have suggested that PPARG promotes urothelial 
differentiation in vitro, our study is the first to demonstrate the function of urothelial PPARG in 
vivo and in specific cell types. We also explored the function of PPARG during UPEC-mediated 
injury and reported that the Pparg-depleted urothelium is more susceptible to develop squamous 
metaplasia. Moreover, PPARG deficiency may predispose the bladder to other pathological 
changes including tumorigenesis. Taken together, our study demonstrated that PPARG is 
important in the establishment, maintenance and regeneration of the urothelium.  
While this study advanced our understating of the function of urothelial PPARG, there 
are always more to explore: 
1) Natural ligands for urothelial PPARG 
PPARG interacts with various compounds that display wide structural diversity. Candidates 
for intrinsic PPARG ligands include the products of cyclooxygenase and lipoxygenase 
metabolism of long chain fatty acids, such as prostaglandins. 15-deoxy-Δ12,14 prostaglandin J2 
(15d-PGJ2) can be produced by the kidney and is detectable in the urine [209]. The umbrella 
cells of the urothelium are in direct contact with urine for extended time, and therefore exposed 
to urinary prostaglandins. This provides a compelling hypothesis for inducing urothelial 
differentiation of the outermost layer of the urothelium. It also explains how exposed 
intermediate cells are signaled for differentiation following the exfoliation of umbrella cells for 
regeneration. However, given its low PPARG affinity (Kd = 2 µM), the physiological 
concentration of 15d-PGJ2 in the urine is much lower than the concentration required to induce 
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PPARG activation. Furthermore, studies in patients with chronically urine-deprived bladders did 
not detect a significant change in their urothelial differentiation [210]. These conflicting results 
post a question to this hypothesis.  
An alternative source of PPARG ligands is the stroma. Epithelial-mesenchymal 
interactions are appreciated as being essential for normal urothelium formation and regeneration. 
Several ligand-receptor pairs have been demonstrated across the basement membrane, including 
SHH, BMP4 and RA signaling [25], [59], [211]. Consistent with this hypothesis, a 
comprehensive analysis of gene expression in different cell types in the bladder from our lab 
showed the expression of Ptgds, a Prostaglandin D2 Synthase, is enriched in a population of 
stromal cells in the bladder. It will be interesting to identify the location of those cells and their 
ability to produce PPARG ligands. 
2) The function of PPARG in energy homeostasis 
Our gene expression profile of the Pparg-ablated urothelium uncovered significant changes 
in genes related to PPARG functions in cellular lipid trafficking and metabolism, and some of 
the genes have been shown to be PPARG targets in other cell types. However, the function of 
those genes in the urothelium remains unclear. Images from transmission electronic microscopy 
of the Pparg-ablated superficial cells showed a decreased number of mitochondria and 
peroxisomes comparing to normal umbrella cells. Given the active trafficking of uroplakins 
between apical membrane and fusiforms, it is not surprising that high energy level is required in 
those cells. This is definitely a potential venue worth further pursuing. 
3) Consequences of over-activation of PPARG 
In this study, we focused on examining the loss of function of Pparg in the urothelium. 
However, mounting data has suggested that over-activation of PPARG also leads to serious 
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consequences. Studies in bladder cancer demonstrated that PPARG gene amplification was 
enriched and its expression was significantly upregulated in the luminal subtype of bladder 
cancer [183]. Further studies showed that PPARG activation contributes to the luminal molecular 
phenotype [181]. Moreover, patients with type 2 diabetes have been reported to have an 
increased risk of bladder cancer, and several PPARG agonists that used to treat type 2 diabetes 
have been withdrawn from the market partially due to this side effect. Given that PPARG 
promotes terminal differentiation of the urothelial cells and suppresses proliferation, it is unlikely 
that PPARG over-activation alone is enough to drive tumor formation. Illustrating the 
consequence from over-activation of PPARG in the urothelium in vivo could help dissect out 
their contributions in promoting the development of luminal subype of bladder cancer and 
provide some insights to improve the designs of therapeutic regimens. 
4) How does PPARG fit into the transcriptional network? 
A couple of transcription factors have been shown to have roles in promoting urothelial 
differentiation, including KLF5, FOXA1, GATA3 and P63 [32], [38], [193], [194]. But their 
interactions remain controversial. Using gene expression profiling in combination with ChIPseq, 
we were able to identify several direct targets of urothelial PPARG, one of the genes that worth 
particular note is Grhl3. Grhl3 has been identified as a crucial regulator of urothelial terminal 
differentiation [66]. Our findings add an important link in the transcriptional network, but more 
connections remain to be elucidated. FOXA1 has been identified as a downstream target of 
PPARG in cultured NHU cells while study from the DeGraff group indicated that FOXA1 and 
PPARG collaborate with each other at a more parallel level. Preliminary data from our lab 
showed no changes in FOXA1 level in the Pparg-ablated urothelium or vice versa, suggesting 
these two transcription factors are less likely directly in the same signaling pathway. 
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Collaborating with other groups to examine different mutants in a systemic way could provide 
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